PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
19755386-5	2009	EXPERIMENTAL DESIGN: We tested the expression of Src tyrosine kinase in Waldenstrom macroglobulinemia and normal cells, and the effect of the specific Src inhibitor AZD0530 on the adhesion, migration, cell cycle, and survival of a Waldenstrom macroglobulinemia cell line and patient samples.	saracatinib	165-172	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	151-154
19755386-7	2009	RESULTS: We show that Src is overexpressed in Waldenstrom macroglobulinemia cells compared with control B cells, and that the use of the Src inhibitor AZD0530 led to significant inhibition of adhesion, migration, and cytoskeletal signaling induced by SDF1.	saracatinib	151-158	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	22-25
19755386-7	2009	RESULTS: We show that Src is overexpressed in Waldenstrom macroglobulinemia cells compared with control B cells, and that the use of the Src inhibitor AZD0530 led to significant inhibition of adhesion, migration, and cytoskeletal signaling induced by SDF1.	saracatinib	151-158	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	137-140
19755386-7	2009	RESULTS: We show that Src is overexpressed in Waldenstrom macroglobulinemia cells compared with control B cells, and that the use of the Src inhibitor AZD0530 led to significant inhibition of adhesion, migration, and cytoskeletal signaling induced by SDF1.	saracatinib	151-158	C-X-C motif chemokine ligand 12	Homo sapiens	251-255
34883449-8	2022	Accordingly, the inhibition of the SRC signaling pathway by saracatinib blocked periplocin-induced proliferation and lipid accumulation in meibomian gland cells.	saracatinib	60-71	Rous sarcoma oncogene	Mus musculus	35-38
34798298-1	2022	OBJECTIVE: To observe the effect of AZD0530 on the progression of knee OA after blocking beta-catenin phosphorylation and then dormancy of the Wnt/beta pathway by tyrosine kinase Fyn.	saracatinib	36-43	catenin beta 1	Homo sapiens	89-101
34798298-1	2022	OBJECTIVE: To observe the effect of AZD0530 on the progression of knee OA after blocking beta-catenin phosphorylation and then dormancy of the Wnt/beta pathway by tyrosine kinase Fyn.	saracatinib	36-43	FYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	179-182
34798298-6	2022	The levels of beta-catenin, p-beta-catenin (Tyr142) and MMP13 in chondrocytes decreased, while the level of Aggrecan increased after AZD0530 was used to intervene chondrocytes in vitro, which was positively correlated with the dose of AZD0530.	saracatinib	133-140	catenin beta 1	Homo sapiens	14-26
34798298-6	2022	The levels of beta-catenin, p-beta-catenin (Tyr142) and MMP13 in chondrocytes decreased, while the level of Aggrecan increased after AZD0530 was used to intervene chondrocytes in vitro, which was positively correlated with the dose of AZD0530.	saracatinib	133-140	catenin beta 1	Homo sapiens	30-42
34798298-6	2022	The levels of beta-catenin, p-beta-catenin (Tyr142) and MMP13 in chondrocytes decreased, while the level of Aggrecan increased after AZD0530 was used to intervene chondrocytes in vitro, which was positively correlated with the dose of AZD0530.	saracatinib	133-140	matrix metallopeptidase 13	Homo sapiens	56-61
34798298-9	2022	AZD0530 can inhibit tyrosine kinase Fyn from beta-catenin phosphorylation, a key Wnt/beta pathway protein, and then inhibit Wnt/beta pathway levels in chondrocytes.	saracatinib	0-7	FYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	36-39
34798298-9	2022	AZD0530 can inhibit tyrosine kinase Fyn from beta-catenin phosphorylation, a key Wnt/beta pathway protein, and then inhibit Wnt/beta pathway levels in chondrocytes.	saracatinib	0-7	catenin beta 1	Homo sapiens	45-57
34830154-8	2021	In mouse TG, a SFKs inhibitor, saracatinib, restored the CGRP release and IL-1beta mRNA level increased by a TRPA1 activator, umbellulone.	saracatinib	31-42	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	57-61
34830154-8	2021	In mouse TG, a SFKs inhibitor, saracatinib, restored the CGRP release and IL-1beta mRNA level increased by a TRPA1 activator, umbellulone.	saracatinib	31-42	interleukin 1 alpha	Mus musculus	74-82
34830154-8	2021	In mouse TG, a SFKs inhibitor, saracatinib, restored the CGRP release and IL-1beta mRNA level increased by a TRPA1 activator, umbellulone.	saracatinib	31-42	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	109-114
34158343-1	2021	AZD0530, a potent small-molecule inhibitor of Src family kinases, is an anti-cancer drug used in the treatment of various cancers.	saracatinib	0-7	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	46-49
34475522-0	2022	Effects of the Fyn kinase inhibitor saracatinib on ventral striatal activity during performance of an fMRI monetary incentive delay task in individuals family history positive or negative for alcohol use disorder.	saracatinib	36-47	FYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	15-18
34158343-4	2021	We show that Src activity of GBM and GSC is increased by radiation and inhibited by AZD0530, and using clonogenic assays, AZD0530 enhances the radiosensitivity of GBM and GSCs.	saracatinib	84-91	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	13-16
34158343-4	2021	We show that Src activity of GBM and GSC is increased by radiation and inhibited by AZD0530, and using clonogenic assays, AZD0530 enhances the radiosensitivity of GBM and GSCs.	saracatinib	122-129	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	13-16
34158343-6	2021	Additionally, AZD0530 was shown to inhibit the radiation-induced EGFR/PI3K/AKT pathway which in known to promote and regulate radioresistance and survival of GBM cells by radiation.	saracatinib	14-21	epidermal growth factor receptor	Homo sapiens	65-69
34158343-6	2021	Additionally, AZD0530 was shown to inhibit the radiation-induced EGFR/PI3K/AKT pathway which in known to promote and regulate radioresistance and survival of GBM cells by radiation.	saracatinib	14-21	AKT serine/threonine kinase 1	Homo sapiens	75-78
34531767-4	2021	The Src/Fyn kinase inhibitor saracatinib (AZD0530) reduces ethanol self-administration and enhances extinction of goal-directed ethanol-seeking in mice.	saracatinib	29-40	Fyn proto-oncogene	Mus musculus	8-11
34531767-4	2021	The Src/Fyn kinase inhibitor saracatinib (AZD0530) reduces ethanol self-administration and enhances extinction of goal-directed ethanol-seeking in mice.	saracatinib	42-49	Fyn proto-oncogene	Mus musculus	8-11
34087381-0	2021	Mechanisms of disease-modifying effect of saracatinib (AZD0530), a Src/Fyn tyrosine kinase inhibitor, in the rat kainate model of temporal lobe epilepsy.	saracatinib	42-53	FYN proto-oncogene, Src family tyrosine kinase	Rattus norvegicus	71-74
34087381-0	2021	Mechanisms of disease-modifying effect of saracatinib (AZD0530), a Src/Fyn tyrosine kinase inhibitor, in the rat kainate model of temporal lobe epilepsy.	saracatinib	55-62	FYN proto-oncogene, Src family tyrosine kinase	Rattus norvegicus	71-74
34087381-2	2021	In this study, we show a significant disease-modifying effect and the mechanisms of a Fyn/Src tyrosine kinase inhibitor, saracatinib (SAR, also known as AZD0530), in the rat kainate (KA) model of TLE.	saracatinib	121-132	FYN proto-oncogene, Src family tyrosine kinase	Rattus norvegicus	86-89
34087381-2	2021	In this study, we show a significant disease-modifying effect and the mechanisms of a Fyn/Src tyrosine kinase inhibitor, saracatinib (SAR, also known as AZD0530), in the rat kainate (KA) model of TLE.	saracatinib	153-160	FYN proto-oncogene, Src family tyrosine kinase	Rattus norvegicus	86-89
33705358-2	2021	From a screen of known biologically active compounds, we identified saracatinib as a potent ALK2 kinase inhibitor.	saracatinib	68-79	activin A receptor, type 1	Mus musculus	92-96
33910400-3	2021	Herein, we further investigated the underlying signaling mechanism of these pro-angiogenic factors after ischemic stroke using a selective Src family inhibitor AZD0530.	saracatinib	160-167	Rous sarcoma oncogene	Mus musculus	139-142
33910400-6	2021	Compared to WT, AZD0530 administration exacerbated spatial cognitive impairments and brain atrophy in EC-miR-15a/16-1 cKO mice following MCAO.	saracatinib	16-23	microRNA 15a	Mus musculus	105-112
33910400-8	2021	Moreover, AZD0530 blocked the Src signaling pathway by downregulating phospho-Src and its downstream mediators (p-Stat3, p-Akt, p-FAK, p-p44/42 MAPK, p-p38 MAPK) in post-ischemic brains.	saracatinib	10-17	Rous sarcoma oncogene	Mus musculus	30-33
33910400-8	2021	Moreover, AZD0530 blocked the Src signaling pathway by downregulating phospho-Src and its downstream mediators (p-Stat3, p-Akt, p-FAK, p-p44/42 MAPK, p-p38 MAPK) in post-ischemic brains.	saracatinib	10-17	Rous sarcoma oncogene	Mus musculus	78-81
33910400-8	2021	Moreover, AZD0530 blocked the Src signaling pathway by downregulating phospho-Src and its downstream mediators (p-Stat3, p-Akt, p-FAK, p-p44/42 MAPK, p-p38 MAPK) in post-ischemic brains.	saracatinib	10-17	signal transducer and activator of transcription 3	Mus musculus	114-119
33910400-8	2021	Moreover, AZD0530 blocked the Src signaling pathway by downregulating phospho-Src and its downstream mediators (p-Stat3, p-Akt, p-FAK, p-p44/42 MAPK, p-p38 MAPK) in post-ischemic brains.	saracatinib	10-17	thymoma viral proto-oncogene 1	Mus musculus	123-126
33910400-8	2021	Moreover, AZD0530 blocked the Src signaling pathway by downregulating phospho-Src and its downstream mediators (p-Stat3, p-Akt, p-FAK, p-p44/42 MAPK, p-p38 MAPK) in post-ischemic brains.	saracatinib	10-17	PTK2 protein tyrosine kinase 2	Mus musculus	130-133
33910400-8	2021	Moreover, AZD0530 blocked the Src signaling pathway by downregulating phospho-Src and its downstream mediators (p-Stat3, p-Akt, p-FAK, p-p44/42 MAPK, p-p38 MAPK) in post-ischemic brains.	saracatinib	10-17	mitogen-activated protein kinase 14	Mus musculus	152-160
34589604-10	2021	Oral administration of saracatinib, a FYN kinase inhibitor, significantly suppressed formation of bone osteolytic lesions in a polyethylene debris-induced osteolysis model.	saracatinib	23-34	FYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	38-41
33410098-0	2021	ActivinA Induced SMAD1/5 Signaling in an iPSC Derived EC Model of Fibrodysplasia Ossificans Progressiva (FOP) Can Be Rescued by the Drug Candidate Saracatinib.	saracatinib	147-158	SMAD family member 1	Homo sapiens	17-24
33705358-3	2021	In enzymatic and cell-based assays, saracatinib preferentially inhibited ALK2 compared with other receptors of the BMP/TGFb signaling pathway, and induced dorsalization in zebrafish embryos consistent with BMP antagonism.	saracatinib	36-47	activin A receptor, type 1 like	Danio rerio	73-77
33451301-0	2021	Post-status epilepticus treatment with the Fyn inhibitor, saracatinib, improves cognitive function in mice.	saracatinib	58-69	Fyn proto-oncogene	Mus musculus	43-46
33334906-7	2021	BRCA2-null prostate cancer cell lines had increased SRC phosphorylation and higher sensitivity to SRC inhibitors (eg, dasatinib, bosutinib, and saracatinib) relative to wild-type cells.	saracatinib	144-155	BRCA2 DNA repair associated	Homo sapiens	0-5
33175322-7	2021	Saracatinib, a nonselective Fyn inhibitor, has already been tested in clinical trials for Alzheimer"s disease, and novel selective Fyn inhibitors are under investigation.	saracatinib	0-11	FYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	28-31
32876513-7	2021	The IGF2BP1-SRC/ERK2 axis is targetable by the SRC-inhibitor saracatinib and MEK-inhibitor selumetinib.	saracatinib	61-72	insulin-like growth factor 2 mRNA binding protein 1	Mus musculus	4-11
32876513-7	2021	The IGF2BP1-SRC/ERK2 axis is targetable by the SRC-inhibitor saracatinib and MEK-inhibitor selumetinib.	saracatinib	61-72	Rous sarcoma oncogene	Mus musculus	12-15
32876513-7	2021	The IGF2BP1-SRC/ERK2 axis is targetable by the SRC-inhibitor saracatinib and MEK-inhibitor selumetinib.	saracatinib	61-72	mitogen-activated protein kinase 1	Mus musculus	16-20
32876513-7	2021	The IGF2BP1-SRC/ERK2 axis is targetable by the SRC-inhibitor saracatinib and MEK-inhibitor selumetinib.	saracatinib	61-72	Rous sarcoma oncogene	Mus musculus	47-50
33451301-4	2021	Saracatinib, a Fyn inhibitor, suppresses epileptogenesis and reduces epileptiform spikes.	saracatinib	0-11	Fyn proto-oncogene	Mus musculus	15-18
33451301-9	2021	CONCLUSIONS: These results showed that saracatinib can improve cognitive functions by reducing the loss of hippocampal neurons after SE, suggesting that Fyn dysfunction is involved in cognitive deficits after SE, and that the inhibition of Fyn is a possible treatment to improve cognitive function in SE patients.	saracatinib	39-50	FYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	153-156
32604782-6	2020	Upon silencing NOX2/4 gene expression and using the SRC inhibitor (AZD0530), progression of TGF-beta1 induced EMT related cellular remodeling, extra cellular matrix (ECM) production, cell migration and invasion, got significantly reverted.	saracatinib	67-74	cytochrome b-245 beta chain	Homo sapiens	15-21
32896567-7	2020	Furthermore, Saracatinib (Src inhibition) and BI2536 (PLK1 inhibition) diminished GSC self-renewal in vitro, and combining the two inhibitors increased survival of orthotopic tumor-bearing mice.	saracatinib	13-24	Rous sarcoma oncogene	Mus musculus	26-29
32692785-7	2020	We found that TBB (a casein kinase II inhibitor), AR and LiCl (GSK-3 inhibitors), cyclosporin A (calcineurin inhibitor), and Saracatinib (Fyn kinase inhibitor) caused robust inhibition of OA-induced monomeric and oligomeric p-tau in both N2a and CTX culture.	saracatinib	125-136	FYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	138-141
32692785-7	2020	We found that TBB (a casein kinase II inhibitor), AR and LiCl (GSK-3 inhibitors), cyclosporin A (calcineurin inhibitor), and Saracatinib (Fyn kinase inhibitor) caused robust inhibition of OA-induced monomeric and oligomeric p-tau in both N2a and CTX culture.	saracatinib	125-136	microtubule associated protein tau	Homo sapiens	226-229
32692785-9	2020	This study provides a comprehensive view of potential drug candidates (TBB, CsA, AR, and Saracatinib), and their efficacy against tau hyperphosphorylation and oligomerization processes.	saracatinib	89-100	microtubule associated protein tau	Homo sapiens	130-133
32372484-7	2020	The brain-permeable c-src inhibitor, saracatinib, efficiently reduces alpha-syn propagation into neighboring regions in an in vivo model system.	saracatinib	37-48	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	20-25
32372484-7	2020	The brain-permeable c-src inhibitor, saracatinib, efficiently reduces alpha-syn propagation into neighboring regions in an in vivo model system.	saracatinib	37-48	synuclein alpha	Homo sapiens	70-79
32635977-3	2020	Phosphorylation of Lyn, Akt, a PI3K substrate, and MAPKs including ERK, JNK, and p38, as well as the intracellular Ca2+ increase induced by this stimulation were also suppressed by saracatinib.	saracatinib	181-192	LYN proto-oncogene, Src family tyrosine kinase	Mus musculus	19-22
32635977-3	2020	Phosphorylation of Lyn, Akt, a PI3K substrate, and MAPKs including ERK, JNK, and p38, as well as the intracellular Ca2+ increase induced by this stimulation were also suppressed by saracatinib.	saracatinib	181-192	thymoma viral proto-oncogene 1	Mus musculus	24-27
32635977-3	2020	Phosphorylation of Lyn, Akt, a PI3K substrate, and MAPKs including ERK, JNK, and p38, as well as the intracellular Ca2+ increase induced by this stimulation were also suppressed by saracatinib.	saracatinib	181-192	mitogen-activated protein kinase 1	Mus musculus	67-70
32635977-3	2020	Phosphorylation of Lyn, Akt, a PI3K substrate, and MAPKs including ERK, JNK, and p38, as well as the intracellular Ca2+ increase induced by this stimulation were also suppressed by saracatinib.	saracatinib	181-192	mitogen-activated protein kinase 8	Mus musculus	72-75
32635977-3	2020	Phosphorylation of Lyn, Akt, a PI3K substrate, and MAPKs including ERK, JNK, and p38, as well as the intracellular Ca2+ increase induced by this stimulation were also suppressed by saracatinib.	saracatinib	181-192	mitogen-activated protein kinase 14	Mus musculus	81-84
32604782-6	2020	Upon silencing NOX2/4 gene expression and using the SRC inhibitor (AZD0530), progression of TGF-beta1 induced EMT related cellular remodeling, extra cellular matrix (ECM) production, cell migration and invasion, got significantly reverted.	saracatinib	67-74	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	52-55
32604782-6	2020	Upon silencing NOX2/4 gene expression and using the SRC inhibitor (AZD0530), progression of TGF-beta1 induced EMT related cellular remodeling, extra cellular matrix (ECM) production, cell migration and invasion, got significantly reverted.	saracatinib	67-74	transforming growth factor beta 1	Homo sapiens	92-101
31801023-10	2020	The chemical inhibitors for c-Src (saracatinib and dasanitib) restored GPX-1 mRNA levels and GPX-1 activity in COPD airway cells in vitro.	saracatinib	35-46	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	28-33
32397949-0	2021	Biophysical and computational view on the in vitro combination between an anticancer drug, saracatinib and human serum albumin.	saracatinib	91-102	albumin	Homo sapiens	113-126
32397949-1	2021	Interaction behaviour of an anticancer drug, saracatinib (SCB) with human serum albumin (HSA), the major carrier protein in human blood circulation was investigated using fluorescence and absorption spectroscopy as well as computational methods.	saracatinib	45-56	albumin	Homo sapiens	74-87
32397949-1	2021	Interaction behaviour of an anticancer drug, saracatinib (SCB) with human serum albumin (HSA), the major carrier protein in human blood circulation was investigated using fluorescence and absorption spectroscopy as well as computational methods.	saracatinib	58-61	albumin	Homo sapiens	74-87
31801023-10	2020	The chemical inhibitors for c-Src (saracatinib and dasanitib) restored GPX-1 mRNA levels and GPX-1 activity in COPD airway cells in vitro.	saracatinib	35-46	glutathione peroxidase 1	Homo sapiens	71-76
31801023-10	2020	The chemical inhibitors for c-Src (saracatinib and dasanitib) restored GPX-1 mRNA levels and GPX-1 activity in COPD airway cells in vitro.	saracatinib	35-46	glutathione peroxidase 1	Homo sapiens	93-98
31801023-11	2020	Similarly, saracatinib prevented the loss of lung Gpx-1 expression in response to chronic smoke exposure in vivo.	saracatinib	11-22	glutathione peroxidase 1	Homo sapiens	50-55
32051399-0	2020	Targeting Src family kinase member Fyn by Saracatinib attenuated liver fibrosis in vitro and in vivo.	saracatinib	42-53	FYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	10-13
32346533-9	2020	However, the addition of the Src family inhibitor saracatinib prevented resistance to vemurafenib in CUL3KD cells and reversed RAC1 activation.	saracatinib	50-61	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	29-32
32346533-9	2020	However, the addition of the Src family inhibitor saracatinib prevented resistance to vemurafenib in CUL3KD cells and reversed RAC1 activation.	saracatinib	50-61	cullin 3	Homo sapiens	101-105
32346533-9	2020	However, the addition of the Src family inhibitor saracatinib prevented resistance to vemurafenib in CUL3KD cells and reversed RAC1 activation.	saracatinib	50-61	Rac family small GTPase 1	Homo sapiens	127-131
32120837-6	2020	Src inhibitor Saracatinib also attenuated TAA-induced expression of type I collagen, alphaSMA, and CTGF in mouse liver tissues.	saracatinib	14-25	Rous sarcoma oncogene	Mus musculus	0-3
32120837-6	2020	Src inhibitor Saracatinib also attenuated TAA-induced expression of type I collagen, alphaSMA, and CTGF in mouse liver tissues.	saracatinib	14-25	actin alpha 2, smooth muscle, aorta	Mus musculus	85-93
32120837-6	2020	Src inhibitor Saracatinib also attenuated TAA-induced expression of type I collagen, alphaSMA, and CTGF in mouse liver tissues.	saracatinib	14-25	cellular communication network factor 2	Mus musculus	99-103
31981897-6	2020	Significantly, Ectopic expression of wild-type AGO2, but not the three tyrosine site mutants, has an obvious tumor-promoting effect in vitro and in vivo, which function could be blocked thoroughly by treatment with c-Src kinase inhibitor, Saracatinib.	saracatinib	239-250	argonaute RISC catalytic component 2	Homo sapiens	47-51
31981897-6	2020	Significantly, Ectopic expression of wild-type AGO2, but not the three tyrosine site mutants, has an obvious tumor-promoting effect in vitro and in vivo, which function could be blocked thoroughly by treatment with c-Src kinase inhibitor, Saracatinib.	saracatinib	239-250	C-terminal Src kinase	Homo sapiens	215-227
32051399-0	2020	Targeting Src family kinase member Fyn by Saracatinib attenuated liver fibrosis in vitro and in vivo.	saracatinib	42-53	Fyn proto-oncogene	Mus musculus	35-38
32051399-11	2020	Saracatinib treatment abolished the activation of Fyn, downregulated the Fyn/FAK/N-WASP signaling in HSCs, and subsequently prevented the activation of HSCs.	saracatinib	0-11	Fyn proto-oncogene	Mus musculus	50-53
32051399-11	2020	Saracatinib treatment abolished the activation of Fyn, downregulated the Fyn/FAK/N-WASP signaling in HSCs, and subsequently prevented the activation of HSCs.	saracatinib	0-11	Fyn proto-oncogene	Mus musculus	73-76
32051399-11	2020	Saracatinib treatment abolished the activation of Fyn, downregulated the Fyn/FAK/N-WASP signaling in HSCs, and subsequently prevented the activation of HSCs.	saracatinib	0-11	PTK2 protein tyrosine kinase 2	Mus musculus	77-80
32051399-11	2020	Saracatinib treatment abolished the activation of Fyn, downregulated the Fyn/FAK/N-WASP signaling in HSCs, and subsequently prevented the activation of HSCs.	saracatinib	0-11	WASP like actin nucleation promoting factor	Mus musculus	81-87
32051399-12	2020	Saracatinib treatment significantly reduced the severity liver fibrosis induced by CCl4 in mice.	saracatinib	0-11	chemokine (C-C motif) ligand 4	Mus musculus	83-87
32051399-15	2020	Fyn inhibitor Saracatinib significantly inhibited HSC activation and attenuated liver fibrosis in mouse model.	saracatinib	14-25	Fyn proto-oncogene	Mus musculus	0-3
31101744-10	2019	After treatment with saracatinib, hippocampal SUVR(WB) in APP/PS1 mice was significantly increased (P = 0.037, paired t test).	saracatinib	21-32	presenilin 1	Mus musculus	62-65
31931755-12	2020	Interference with ABCG1 expression or inhibition of Wnt signaling resulted in reversal of the saracatinib-induced oxaliplatin resistance in HCC.	saracatinib	94-105	ATP binding cassette subfamily G member 1	Homo sapiens	18-23
31931755-13	2020	CONCLUSIONS: These studies demonstrated that combined or sequential chemotherapy with oxaliplatin and saracatinib reduced antitumor efficacy, and this antagonism was attributed to the activation of Wnt signaling and upregulation of ABCG1 by saracatinib.	saracatinib	102-113	ATP binding cassette subfamily G member 1	Homo sapiens	232-237
31931755-0	2020	Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma.	saracatinib	38-49	ATP binding cassette subfamily G member 1	Homo sapiens	71-76
31805962-0	2019	Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.	saracatinib	43-54	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	28-31
31805962-0	2019	Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.	saracatinib	43-54	AKT serine/threonine kinase 1	Homo sapiens	36-39
31805962-0	2019	Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.	saracatinib	43-54	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	126-129
31805962-4	2019	METHODS: Dual drug-loaded nanoparticles (NPs) were developed to co-deliver Src inhibitor saracatinib (AZD0530) and AKT inhibitor capivasertib (AZD5363) into the same population of tumor cells.	saracatinib	89-100	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	75-78
31805962-4	2019	METHODS: Dual drug-loaded nanoparticles (NPs) were developed to co-deliver Src inhibitor saracatinib (AZD0530) and AKT inhibitor capivasertib (AZD5363) into the same population of tumor cells.	saracatinib	102-109	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	75-78
31805962-10	2019	Cathepsin B-sensitive NPs for co-delivering saracatinib and capivasertib significantly improved the efficacy of tumor repression without increasing side effects, which were due to highly specific tumor-targeting drug delivery system and synergistic anticancer effects by co-inactivation of AKT and Src in HNSCC cells.	saracatinib	44-55	cathepsin B	Homo sapiens	0-11
31805962-10	2019	Cathepsin B-sensitive NPs for co-delivering saracatinib and capivasertib significantly improved the efficacy of tumor repression without increasing side effects, which were due to highly specific tumor-targeting drug delivery system and synergistic anticancer effects by co-inactivation of AKT and Src in HNSCC cells.	saracatinib	44-55	AKT serine/threonine kinase 1	Homo sapiens	290-293
31805962-10	2019	Cathepsin B-sensitive NPs for co-delivering saracatinib and capivasertib significantly improved the efficacy of tumor repression without increasing side effects, which were due to highly specific tumor-targeting drug delivery system and synergistic anticancer effects by co-inactivation of AKT and Src in HNSCC cells.	saracatinib	44-55	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	298-301
31101744-13	2019	Conclusion: On the basis of the 11C-UCB-J PET results, hippocampal synaptic density was lower in APP/PS1 mice than in WT mice at baseline, and this deficit was normalized by treatment with saracatinib.	saracatinib	189-200	presenilin 1	Mus musculus	101-104
30536923-0	2019	The Fyn kinase inhibitor, AZD0530, suppresses mouse alcohol self-administration and seeking.	saracatinib	26-33	Fyn proto-oncogene	Mus musculus	4-7
30536923-3	2019	Here, we used AZD0530, a CNS penetrable inhibitor of Src PTKs developed for the treatment of Alzheimer disease and cancer and tested its efficacy to suppress alcohol-dependent molecular and behavioral effects.	saracatinib	14-21	Fyn proto-oncogene	Mus musculus	53-56
30536923-4	2019	We show that systemic administration of AZD0530 prevents alcohol-induced Fyn activation and GluN2B phosphorylation in the DMS of mice.	saracatinib	40-47	Fyn proto-oncogene	Mus musculus	73-76
30536923-4	2019	We show that systemic administration of AZD0530 prevents alcohol-induced Fyn activation and GluN2B phosphorylation in the DMS of mice.	saracatinib	40-47	glutamate receptor, ionotropic, NMDA2B (epsilon 2)	Mus musculus	92-98
30536923-6	2019	Together, our findings suggest that AZD0530, through its inhibitory actions on Fyn kinase, dampens alcohol seeking and drinking.	saracatinib	36-43	Fyn proto-oncogene	Mus musculus	79-82
31667062-0	2019	An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain.	saracatinib	87-98	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	66-69
31416844-6	2019	However, we show that the SRC inhibitor, saracatinib, can block the DBL-driven resistance.	saracatinib	41-52	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	26-29
31416844-6	2019	However, we show that the SRC inhibitor, saracatinib, can block the DBL-driven resistance.	saracatinib	41-52	MCF.2 cell line derived transforming sequence	Homo sapiens	68-71
31329216-2	2019	AZD0530 is an investigational kinase inhibitor specific for the Src family, including fyn, that has been repurposed for the treatment of Alzheimer disease.	saracatinib	0-7	FYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	64-67
31329216-2	2019	AZD0530 is an investigational kinase inhibitor specific for the Src family, including fyn, that has been repurposed for the treatment of Alzheimer disease.	saracatinib	0-7	FYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	86-89
31667062-3	2019	The non-receptor tyrosine kinase Src is thought to act as a hub for regulating NMDA receptor activity and the orally available Src inhibitor saracatinib has shown promise as a potential analgesic in recent animal studies.	saracatinib	141-152	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	127-130
30504771-7	2018	Pharmaceutical intervention with AZD0530 markedly reverses LIF-mediated cancer dissemination and local invasion through promotion of cytoplasmic accumulation of YAP1 and suppression of focal adhesion kinases.	saracatinib	33-40	Yes1 associated transcriptional regulator	Homo sapiens	161-165
30628679-10	2019	However, blocking Src activity with saracatinib prevented CX3CL1-mediated cell migration and invasion.	saracatinib	36-47	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	18-21
30628679-10	2019	However, blocking Src activity with saracatinib prevented CX3CL1-mediated cell migration and invasion.	saracatinib	36-47	C-X3-C motif chemokine ligand 1	Homo sapiens	58-64
30207834-5	2019	SRC pathway inhibition by Saracatinib resulted in reduced TLK2-mediated glioblastoma migration, invasion, confirming a key role for SRC signaling in regulating the functions of TLK2.	saracatinib	26-37	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	0-3
30207834-5	2019	SRC pathway inhibition by Saracatinib resulted in reduced TLK2-mediated glioblastoma migration, invasion, confirming a key role for SRC signaling in regulating the functions of TLK2.	saracatinib	26-37	tousled like kinase 2	Homo sapiens	58-62
30207834-5	2019	SRC pathway inhibition by Saracatinib resulted in reduced TLK2-mediated glioblastoma migration, invasion, confirming a key role for SRC signaling in regulating the functions of TLK2.	saracatinib	26-37	tousled like kinase 2	Homo sapiens	177-181
30817315-5	2019	Mechanism studies revealed that the induction of SAA1 expression by cortisol and SAA1 was blocked by either the transcription factor STAT3 antagonist AZD0530 or siRNA-mediated knockdown of STAT3.	saracatinib	150-157	serum amyloid A1	Homo sapiens	49-53
30817315-5	2019	Mechanism studies revealed that the induction of SAA1 expression by cortisol and SAA1 was blocked by either the transcription factor STAT3 antagonist AZD0530 or siRNA-mediated knockdown of STAT3.	saracatinib	150-157	serum amyloid A1	Homo sapiens	81-85
30817315-5	2019	Mechanism studies revealed that the induction of SAA1 expression by cortisol and SAA1 was blocked by either the transcription factor STAT3 antagonist AZD0530 or siRNA-mediated knockdown of STAT3.	saracatinib	150-157	signal transducer and activator of transcription 3	Homo sapiens	133-138
30166523-10	2018	A Src inhibitor saracatinib sensitized esophageal cancer cells to irradiation.	saracatinib	16-27	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	2-5
29959144-6	2018	Treatment of established lines and primary ovarian cancer cultures with Src and MEK inhibitors saracatinib and selumetinib, respectively, showed target kinase inhibition and synergistic induction of apoptosis and cell-cycle arrest in vitro, and tumor inhibition in xenografts.	saracatinib	95-106	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	72-75
29959144-6	2018	Treatment of established lines and primary ovarian cancer cultures with Src and MEK inhibitors saracatinib and selumetinib, respectively, showed target kinase inhibition and synergistic induction of apoptosis and cell-cycle arrest in vitro, and tumor inhibition in xenografts.	saracatinib	95-106	mitogen-activated protein kinase kinase 7	Homo sapiens	80-83
29530864-5	2018	Astonishingly, the transport efficiencies (TEs) of ETT for saracatinib and some nucleoside drugs were as high as the TE for ET.	saracatinib	59-70	solute carrier family 22 member 4	Homo sapiens	51-54
29555825-10	2018	Fyn inhibitors AZD0530 and PP1 significantly attenuated OA progression by blocking the beta-catenin pathway and reducing the levels of extracellular matrix catabolic enzymes in the articular cartilage.	saracatinib	15-22	Fyn proto-oncogene	Mus musculus	0-3
29555825-10	2018	Fyn inhibitors AZD0530 and PP1 significantly attenuated OA progression by blocking the beta-catenin pathway and reducing the levels of extracellular matrix catabolic enzymes in the articular cartilage.	saracatinib	15-22	catenin (cadherin associated protein), beta 1	Mus musculus	87-99
29401603-10	2018	HBc-induced cellular proliferation and tumor formation were reversed by administration of the Src inhibitor saracatinib.	saracatinib	108-119	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	94-97
29925404-10	2018	Mechanistic assessment of the drug effects in HNSCC cells showed that saracatinib induced suppression of Src-dependent invasion/metastasis through downregulating the expression levels of Vimentin and Snail proteins.	saracatinib	70-81	vimentin	Mus musculus	187-195
29925404-10	2018	Mechanistic assessment of the drug effects in HNSCC cells showed that saracatinib induced suppression of Src-dependent invasion/metastasis through downregulating the expression levels of Vimentin and Snail proteins.	saracatinib	70-81	snail family zinc finger 1	Mus musculus	200-205
29601121-4	2018	In our study, we established an Src inhibitor saracatinib-resistant breast cancer cell line (SKBR-3/SI) for the first time and by evaluating mRNA expression profile, we found that plasminogen activator inhibitor-1 (PAI-1) was upregulated in saracatinib-resistant cells compared to the parent cells.	saracatinib	46-57	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	32-35
29601121-4	2018	In our study, we established an Src inhibitor saracatinib-resistant breast cancer cell line (SKBR-3/SI) for the first time and by evaluating mRNA expression profile, we found that plasminogen activator inhibitor-1 (PAI-1) was upregulated in saracatinib-resistant cells compared to the parent cells.	saracatinib	46-57	serpin family E member 1	Homo sapiens	180-213
29601121-4	2018	In our study, we established an Src inhibitor saracatinib-resistant breast cancer cell line (SKBR-3/SI) for the first time and by evaluating mRNA expression profile, we found that plasminogen activator inhibitor-1 (PAI-1) was upregulated in saracatinib-resistant cells compared to the parent cells.	saracatinib	46-57	serpin family E member 1	Homo sapiens	215-220
29601121-4	2018	In our study, we established an Src inhibitor saracatinib-resistant breast cancer cell line (SKBR-3/SI) for the first time and by evaluating mRNA expression profile, we found that plasminogen activator inhibitor-1 (PAI-1) was upregulated in saracatinib-resistant cells compared to the parent cells.	saracatinib	241-252	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	32-35
29601121-4	2018	In our study, we established an Src inhibitor saracatinib-resistant breast cancer cell line (SKBR-3/SI) for the first time and by evaluating mRNA expression profile, we found that plasminogen activator inhibitor-1 (PAI-1) was upregulated in saracatinib-resistant cells compared to the parent cells.	saracatinib	241-252	serpin family E member 1	Homo sapiens	180-213
29601121-4	2018	In our study, we established an Src inhibitor saracatinib-resistant breast cancer cell line (SKBR-3/SI) for the first time and by evaluating mRNA expression profile, we found that plasminogen activator inhibitor-1 (PAI-1) was upregulated in saracatinib-resistant cells compared to the parent cells.	saracatinib	241-252	serpin family E member 1	Homo sapiens	215-220
29601121-5	2018	Further study demonstrated that PAI-1 might induce saracatinib resistance in breast cancer cells by increasing the secretion of chemokine (C-C motif) ligand 5 (CCL5).	saracatinib	51-62	serpin family E member 1	Homo sapiens	32-37
29601121-5	2018	Further study demonstrated that PAI-1 might induce saracatinib resistance in breast cancer cells by increasing the secretion of chemokine (C-C motif) ligand 5 (CCL5).	saracatinib	51-62	C-C motif chemokine ligand 5	Homo sapiens	128-158
29601121-5	2018	Further study demonstrated that PAI-1 might induce saracatinib resistance in breast cancer cells by increasing the secretion of chemokine (C-C motif) ligand 5 (CCL5).	saracatinib	51-62	C-C motif chemokine ligand 5	Homo sapiens	160-164
29601121-6	2018	Functional assays showed that PAI-1 and CCL5 overexpression promoted cell proliferation and migration in breast cancer cells, while inhibition of PAI-1 and CCL5 decreased cell proliferation and migration in saracatinib-resistant cells.	saracatinib	207-218	serpin family E member 1	Homo sapiens	146-151
29601121-6	2018	Functional assays showed that PAI-1 and CCL5 overexpression promoted cell proliferation and migration in breast cancer cells, while inhibition of PAI-1 and CCL5 decreased cell proliferation and migration in saracatinib-resistant cells.	saracatinib	207-218	C-C motif chemokine ligand 5	Homo sapiens	156-160
29601121-7	2018	We also showed that targeting PAI-1 or CCL5 could reverse saracatinib resistance, which deserves more attention in clinical settings.	saracatinib	58-69	serpin family E member 1	Homo sapiens	30-35
29601121-7	2018	We also showed that targeting PAI-1 or CCL5 could reverse saracatinib resistance, which deserves more attention in clinical settings.	saracatinib	58-69	C-C motif chemokine ligand 5	Homo sapiens	39-43
29435137-4	2018	Using two complementary strategies; a targeted tumour suppressor gene siRNA screen, and a phospho-receptor tyrosine kinase array, we demonstrate that activation of MAPK signalling, via a reduction in NF1 (neurofibromin) expression or overexpression of HER2 and the insulin receptor, can drive resistance to AZD0530.	saracatinib	307-314	mitogen-activated protein kinase 1	Homo sapiens	164-168
28840468-9	2018	Pre-administration of saracatinib (AZD0530), an inhibitor of Fyn activity, also significantly reduced LID in dyskinetic wild-type mice.	saracatinib	22-33	Fyn proto-oncogene	Mus musculus	61-64
28840468-9	2018	Pre-administration of saracatinib (AZD0530), an inhibitor of Fyn activity, also significantly reduced LID in dyskinetic wild-type mice.	saracatinib	35-42	Fyn proto-oncogene	Mus musculus	61-64
29550144-0	2018	miR-19b-3p inhibits breast cancer cell proliferation and reverses saracatinib-resistance by regulating PI3K/Akt pathway.	saracatinib	66-77	microRNA 19b-1	Homo sapiens	0-7
29550144-0	2018	miR-19b-3p inhibits breast cancer cell proliferation and reverses saracatinib-resistance by regulating PI3K/Akt pathway.	saracatinib	66-77	AKT serine/threonine kinase 1	Homo sapiens	108-111
29550144-6	2018	In this study, we established a Src inhibitor saracatinib-resistant breast cancer cell line (SK-BR-3/SI) for the first time.	saracatinib	46-57	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	32-35
29550144-7	2018	Microarray data and qRT-PCR results showed that miR-19b-3p expression was downregulated in saracatinib-resistant cells compared with saracatinib-sensitive cells.	saracatinib	91-102	microRNA 19b-1	Homo sapiens	48-55
29550144-7	2018	Microarray data and qRT-PCR results showed that miR-19b-3p expression was downregulated in saracatinib-resistant cells compared with saracatinib-sensitive cells.	saracatinib	133-144	microRNA 19b-1	Homo sapiens	48-55
29550144-8	2018	Downregulation of miR-19b-3p remarkably increased the IC50 value of saracatinib, and promoted cell migration.	saracatinib	68-79	microRNA 19b-1	Homo sapiens	18-25
29191754-2	2018	Because no investigational agents have demonstrated disease-modifying effects clinically, we tested whether the Fyn inhibitor, saracatinib, provides persistent improvement in a transgenic model.	saracatinib	127-138	Fyn proto-oncogene	Mus musculus	112-115
29535838-8	2018	Dasatinib and saracatinib have potent inhibitory effects on Yes and treatment with either resulted in downregulation of YAP1 transcription targets, reduced cell viability, and G0-G1 cell cycle arrest.	saracatinib	14-25	Yes1 associated transcriptional regulator	Homo sapiens	120-124
29435137-0	2018	Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer.	saracatinib	55-66	mitogen-activated protein kinase 1	Homo sapiens	14-18
29435137-0	2018	Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer.	saracatinib	68-75	mitogen-activated protein kinase 1	Homo sapiens	14-18
29435137-2	2018	The SAPPROC trial investigated the addition of the SRC inhibitor saracatinib (AZD0530) to weekly paclitaxel for the treatment of platinum resistant ovarian cancer; however, this drug combination did not provide any benefit to progression free survival (PFS) of women with platinum resistant disease.	saracatinib	65-76	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	51-54
29435137-2	2018	The SAPPROC trial investigated the addition of the SRC inhibitor saracatinib (AZD0530) to weekly paclitaxel for the treatment of platinum resistant ovarian cancer; however, this drug combination did not provide any benefit to progression free survival (PFS) of women with platinum resistant disease.	saracatinib	78-85	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	51-54
29435137-5	2018	Knockdown of NF1 in two ovarian cancer cell lines resulted in resistance to AZD0530, and was accompanied with activated MEK and ERK signalling.	saracatinib	76-83	neurofibromin 1	Homo sapiens	13-16
29435137-6	2018	We also show that silencing of HER2 and the insulin receptor can partially resensitize AZD0530 resistant cells, which was associated with decreased phosphorylation of MEK and ERK.	saracatinib	87-94	erb-b2 receptor tyrosine kinase 2	Homo sapiens	31-35
29435137-6	2018	We also show that silencing of HER2 and the insulin receptor can partially resensitize AZD0530 resistant cells, which was associated with decreased phosphorylation of MEK and ERK.	saracatinib	87-94	insulin receptor	Homo sapiens	44-60
29435137-6	2018	We also show that silencing of HER2 and the insulin receptor can partially resensitize AZD0530 resistant cells, which was associated with decreased phosphorylation of MEK and ERK.	saracatinib	87-94	mitogen-activated protein kinase kinase 7	Homo sapiens	167-170
29435137-6	2018	We also show that silencing of HER2 and the insulin receptor can partially resensitize AZD0530 resistant cells, which was associated with decreased phosphorylation of MEK and ERK.	saracatinib	87-94	mitogen-activated protein kinase 1	Homo sapiens	175-178
29435137-7	2018	Furthermore, we demonstrate a synergistic effect of combining SRC and MEK inhibitors in both AZD0530 sensitive and resistant cells, and that MEK inhibition is sufficient to completely resensitize AZD0530 resistant cells.	saracatinib	93-100	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	62-65
29435137-7	2018	Furthermore, we demonstrate a synergistic effect of combining SRC and MEK inhibitors in both AZD0530 sensitive and resistant cells, and that MEK inhibition is sufficient to completely resensitize AZD0530 resistant cells.	saracatinib	93-100	mitogen-activated protein kinase kinase 7	Homo sapiens	70-73
29435137-7	2018	Furthermore, we demonstrate a synergistic effect of combining SRC and MEK inhibitors in both AZD0530 sensitive and resistant cells, and that MEK inhibition is sufficient to completely resensitize AZD0530 resistant cells.	saracatinib	196-203	mitogen-activated protein kinase kinase 7	Homo sapiens	141-144
29021139-5	2017	Inhibition of Pxn phosphorylation by the Src inhibitor saracatinib or its knockdown via shRNA dramatically altered adhesion and spreading of freshly isolated CD8+/CD103+ lung tumor-infiltrating lymphocytes and CD103+ tumor-specific CTL clones.	saracatinib	55-66	paxillin	Homo sapiens	14-17
29021139-5	2017	Inhibition of Pxn phosphorylation by the Src inhibitor saracatinib or its knockdown via shRNA dramatically altered adhesion and spreading of freshly isolated CD8+/CD103+ lung tumor-infiltrating lymphocytes and CD103+ tumor-specific CTL clones.	saracatinib	55-66	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	41-44
29021139-5	2017	Inhibition of Pxn phosphorylation by the Src inhibitor saracatinib or its knockdown via shRNA dramatically altered adhesion and spreading of freshly isolated CD8+/CD103+ lung tumor-infiltrating lymphocytes and CD103+ tumor-specific CTL clones.	saracatinib	55-66	CD8a molecule	Homo sapiens	158-161
29021139-5	2017	Inhibition of Pxn phosphorylation by the Src inhibitor saracatinib or its knockdown via shRNA dramatically altered adhesion and spreading of freshly isolated CD8+/CD103+ lung tumor-infiltrating lymphocytes and CD103+ tumor-specific CTL clones.	saracatinib	55-66	integrin subunit alpha E	Homo sapiens	163-168
29021139-5	2017	Inhibition of Pxn phosphorylation by the Src inhibitor saracatinib or its knockdown via shRNA dramatically altered adhesion and spreading of freshly isolated CD8+/CD103+ lung tumor-infiltrating lymphocytes and CD103+ tumor-specific CTL clones.	saracatinib	55-66	integrin subunit alpha E	Homo sapiens	210-215
29021139-6	2017	Inhibition of Pxn phosphorylation with saracatinib in these CTL clones also severely compromised their functional activities toward autologous tumor cells.	saracatinib	39-50	paxillin	Homo sapiens	14-17
28818835-5	2017	The intracerebroventricular or stereotaxic injection of a Src inhibitor (AZD0530), or Src shRNA viruses attenuated pY336 levels, and several somatic withdrawal signs.	saracatinib	73-80	Rous sarcoma oncogene	Mus musculus	58-61
28116540-9	2017	Inhibition of SRC by Saracatinib (SARC) blocked GDNF function and accelerated TZMB-mediated cell death in TSTC, but GDNF continued promoting TRTC growth.	saracatinib	21-32	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	14-17
28775147-5	2017	We demonstrated that merlin-deficient mouse Schwann cells (MD-MSC) treated with the c-Met inhibitor, cabozantinib, or the Src kinase inhibitors, dasatinib and saracatinib, underwent a G1 cell-cycle arrest.	saracatinib	159-170	neurofibromin 2	Mus musculus	21-27
28775147-5	2017	We demonstrated that merlin-deficient mouse Schwann cells (MD-MSC) treated with the c-Met inhibitor, cabozantinib, or the Src kinase inhibitors, dasatinib and saracatinib, underwent a G1 cell-cycle arrest.	saracatinib	159-170	Rous sarcoma oncogene	Mus musculus	122-125
28775147-8	2017	Moreover, human vestibular schwannoma cells with NF2 mutations had a 40% decrease in cell viability when treated with cabozantinib and saracatinib together compared with the vehicle control.	saracatinib	135-146	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	49-52
29066500-9	2017	We demonstrated that tumor outgrowth from PTPN23-deficient BT474 cells was suppressed in a xenograft model in vivo upon treatment with AZD0530, an SFK inhibitor.	saracatinib	135-142	protein tyrosine phosphatase non-receptor type 23	Homo sapiens	42-48
28838952-5	2017	Targeting LCK signaling via saracatinib, an inhibitor currently undergoing clinical evaluation, sensitized chemoresistant cells to cisplatin.	saracatinib	28-39	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	10-13
28455521-0	2017	Importance of the novel organic cation transporter 1 for tyrosine kinase inhibition by saracatinib in rheumatoid arthritis synovial fibroblasts.	saracatinib	87-98	TXK tyrosine kinase	Homo sapiens	57-72
28455521-3	2017	Since intracellular effective TKIs must enter the cell to reach their intracellular targets, here we investigated the interaction of the TKI saracatinib, a dual inhibitor of c-Src and c-Abl signaling, with transporters for organic cations as well as the role of these transporters for the biological effect of saracatinib in human RA-synovial fibroblasts (hRASF).	saracatinib	141-152	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	174-179
28455521-3	2017	Since intracellular effective TKIs must enter the cell to reach their intracellular targets, here we investigated the interaction of the TKI saracatinib, a dual inhibitor of c-Src and c-Abl signaling, with transporters for organic cations as well as the role of these transporters for the biological effect of saracatinib in human RA-synovial fibroblasts (hRASF).	saracatinib	141-152	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	184-189
28455521-5	2017	The cellular saracatinib uptake was mainly dependent on the human novel organic cation transporter 1 (hOCTN1), which showed the highest apparent affinity for saracatinib among all other transporters for organic cations analyzed here.	saracatinib	13-24	solute carrier family 22 member 4	Homo sapiens	102-108
28455521-5	2017	The cellular saracatinib uptake was mainly dependent on the human novel organic cation transporter 1 (hOCTN1), which showed the highest apparent affinity for saracatinib among all other transporters for organic cations analyzed here.	saracatinib	158-169	solute carrier family 22 member 4	Homo sapiens	102-108
28455521-6	2017	In hRASF, saracatinib biologic function was dependent on hOCTN1.	saracatinib	10-21	solute carrier family 22 member 4	Homo sapiens	57-63
28455521-7	2017	Further analysis showed that disease specific factors (pH, inflammatory cytokines such as TNFalpha) regulated saracatinib uptake in hRASF.	saracatinib	110-121	tumor necrosis factor	Homo sapiens	90-98
28561330-21	2017	In old arteries, Src inhibition (saracatinib) increased: (i) 140 kDa VE-cadherin in the TTX-insoluble fraction, (ii) VE-cadherin intensity at AJs, (iii) AJ width, and (iv) acetylcholine dilatation.	saracatinib	33-44	SRC proto-oncogene, non-receptor tyrosine kinase	Rattus norvegicus	17-20
28561330-21	2017	In old arteries, Src inhibition (saracatinib) increased: (i) 140 kDa VE-cadherin in the TTX-insoluble fraction, (ii) VE-cadherin intensity at AJs, (iii) AJ width, and (iv) acetylcholine dilatation.	saracatinib	33-44	cadherin 5	Rattus norvegicus	69-80
28561330-21	2017	In old arteries, Src inhibition (saracatinib) increased: (i) 140 kDa VE-cadherin in the TTX-insoluble fraction, (ii) VE-cadherin intensity at AJs, (iii) AJ width, and (iv) acetylcholine dilatation.	saracatinib	33-44	cadherin 5	Rattus norvegicus	117-128
28116540-9	2017	Inhibition of SRC by Saracatinib (SARC) blocked GDNF function and accelerated TZMB-mediated cell death in TSTC, but GDNF continued promoting TRTC growth.	saracatinib	21-32	glial cell derived neurotrophic factor	Homo sapiens	48-52
28396832-0	2017	AZD0530 sensitizes drug-resistant ALK-positive lung cancer cells by inhibiting SRC signaling.	saracatinib	0-7	ALK receptor tyrosine kinase	Homo sapiens	34-37
28396832-0	2017	AZD0530 sensitizes drug-resistant ALK-positive lung cancer cells by inhibiting SRC signaling.	saracatinib	0-7	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	79-82
28396832-5	2017	Furthermore, SRC inhibition by AZD0530 was effective in ALK-resistant cancer cells.	saracatinib	31-38	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	13-16
28396832-5	2017	Furthermore, SRC inhibition by AZD0530 was effective in ALK-resistant cancer cells.	saracatinib	31-38	ALK receptor tyrosine kinase	Homo sapiens	56-59
28396832-6	2017	Thus, ALK inhibition by ceritinib may lead to upregulation of SRC signaling, and AZD0530 could serve as a potential drug in the clinic to treat ALK-resistant lung cancer patients.	saracatinib	81-88	ALK receptor tyrosine kinase	Homo sapiens	144-147
27460949-5	2016	Phosphorylation level of Src pathway signalling molecules, such as Src, FAK and Stat3, were also reduced in vitro and in vivo, as a result of the anti-metastasic effects caused by saracatinib treatment.	saracatinib	180-191	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	25-28
28049762-7	2017	Pharmacological inhibition of Src with AZD0530 and clustered regularly interspaced short palindromic repeats/Cas9-mediated knockout of Src demonstrated that Src was critical for activating the TBK1-IRF3 pathway and stimulating type I IFN production.	saracatinib	39-46	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	30-33
27766744-0	2016	PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines.	saracatinib	31-42	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	0-5
27766744-3	2016	We explored the sensitivity of ovarian cancer cell lines to the Src kinase inhibitor saracatinib to identify predictive markers of drug sensitivity using gene microarrays.	saracatinib	85-96	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	64-67
27766744-4	2016	Pituitary tumor transforming gene 1 (PTTG1) was selected as a potential biomarker as mRNA levels were correlated with saracatinib resistance, as well as higher PTTG1 protein expression.	saracatinib	118-129	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	0-35
27766744-4	2016	Pituitary tumor transforming gene 1 (PTTG1) was selected as a potential biomarker as mRNA levels were correlated with saracatinib resistance, as well as higher PTTG1 protein expression.	saracatinib	118-129	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	37-42
27766744-6	2016	In sensitive cell lines, saracatinib treatment decreased PTTG1 and fibroblast growth factor 2 (FGF2) protein levels.	saracatinib	25-36	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	57-62
27766744-6	2016	In sensitive cell lines, saracatinib treatment decreased PTTG1 and fibroblast growth factor 2 (FGF2) protein levels.	saracatinib	25-36	fibroblast growth factor 2	Homo sapiens	67-93
27766744-6	2016	In sensitive cell lines, saracatinib treatment decreased PTTG1 and fibroblast growth factor 2 (FGF2) protein levels.	saracatinib	25-36	fibroblast growth factor 2	Homo sapiens	95-99
27766744-7	2016	Downregulating PTTG1 by siRNAs increased saracatinib sensitivity in two resistant cell lines.	saracatinib	41-52	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	15-20
27766744-8	2016	Our results indicate PTTG1 may be a valuable biomarker in ovarian cancer to predict sensitivity to saracatinib, and could form the basis of a targeted prospective saracatinib trial for ovarian cancer.	saracatinib	99-110	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	21-26
27766744-8	2016	Our results indicate PTTG1 may be a valuable biomarker in ovarian cancer to predict sensitivity to saracatinib, and could form the basis of a targeted prospective saracatinib trial for ovarian cancer.	saracatinib	163-174	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	21-26
28036386-5	2016	Inhibition of src by both saracatinib (AZD0530) and siRNA could partially reverse gemcitabine resistance and attenuate resistance-associated anti-apoptosis, migration and stem cell capacities.	saracatinib	26-37	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	14-17
28036386-5	2016	Inhibition of src by both saracatinib (AZD0530) and siRNA could partially reverse gemcitabine resistance and attenuate resistance-associated anti-apoptosis, migration and stem cell capacities.	saracatinib	39-46	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	14-17
27666484-0	2016	Combined SRC inhibitor saracatinib and anti-ErbB2 antibody H2-18 produces a synergistic antitumor effect on trastuzumab-resistant breast cancer.	saracatinib	23-34	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	9-12
27666484-3	2016	Recently, Src inhibitor saracatinib has drawn great attention for its key role in trastuzumab response.	saracatinib	24-35	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	10-13
27666484-8	2016	H2-18 plus saracatinib showed a significantly more potent PCD-inducing activity compared with either H2-18 or saracatinib alone.	saracatinib	110-121	sphingosine-1-phosphate receptor 2	Homo sapiens	0-5
27475932-4	2016	The present study provides preclinical evidence that Delta16HER2 expression confers de novo resistance to standard anti-HER2-therapies such as Lapatinib and acquired resistance to the selective Src inhibitor Saracatinib in breast cancer.	saracatinib	208-219	erb-b2 receptor tyrosine kinase 2	Homo sapiens	60-64
27475932-4	2016	The present study provides preclinical evidence that Delta16HER2 expression confers de novo resistance to standard anti-HER2-therapies such as Lapatinib and acquired resistance to the selective Src inhibitor Saracatinib in breast cancer.	saracatinib	208-219	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	194-197
27460949-5	2016	Phosphorylation level of Src pathway signalling molecules, such as Src, FAK and Stat3, were also reduced in vitro and in vivo, as a result of the anti-metastasic effects caused by saracatinib treatment.	saracatinib	180-191	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	67-70
27460949-5	2016	Phosphorylation level of Src pathway signalling molecules, such as Src, FAK and Stat3, were also reduced in vitro and in vivo, as a result of the anti-metastasic effects caused by saracatinib treatment.	saracatinib	180-191	protein tyrosine kinase 2	Homo sapiens	72-75
27460949-5	2016	Phosphorylation level of Src pathway signalling molecules, such as Src, FAK and Stat3, were also reduced in vitro and in vivo, as a result of the anti-metastasic effects caused by saracatinib treatment.	saracatinib	180-191	signal transducer and activator of transcription 3	Homo sapiens	80-85
26941850-7	2016	In our study, Src kinase activity in cultured cells and tumor xenografts was monitored quantitatively and dynamically in response to clinical small-molecular kinase inhibitors, dasatinib and saracatinib.	saracatinib	191-202	Rous sarcoma oncogene	Mus musculus	14-17
27095574-0	2016	SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.	saracatinib	27-38	Rous sarcoma oncogene	Mus musculus	0-3
27095574-3	2016	In the current study, we investigated the effect of treatment with the SRC inhibitor saracatinib (AZD0530) on osteoclast and osteoblast differentiation and function, and on the development of MM and its associated bone disease in the 5TGM.1 and 5T2MM murine MM models.	saracatinib	85-96	Rous sarcoma oncogene	Mus musculus	71-74
27095574-3	2016	In the current study, we investigated the effect of treatment with the SRC inhibitor saracatinib (AZD0530) on osteoclast and osteoblast differentiation and function, and on the development of MM and its associated bone disease in the 5TGM.1 and 5T2MM murine MM models.	saracatinib	98-105	Rous sarcoma oncogene	Mus musculus	71-74
27094550-7	2016	We have tested this hypothesis using an orally bioavailable Src inhibitor (saracatinib) in a rat model of cancer-induced bone pain.	saracatinib	75-86	SRC proto-oncogene, non-receptor tyrosine kinase	Rattus norvegicus	60-63
27094550-10	2016	The analgesic mechanisms of saracatinib appear to be due to an effect on the nervous system as immunoblotting of L2-5 spinal segments showed that mammary rat metastasis tumor cells-1 injection induced phosphorylation of the GluN1 subunit of the N-methyl-D-aspartate receptor, indicative of receptor activation, and this was reduced by saracatinib.	saracatinib	28-39	glutamate ionotropic receptor NMDA type subunit 1	Rattus norvegicus	224-229
27094550-10	2016	The analgesic mechanisms of saracatinib appear to be due to an effect on the nervous system as immunoblotting of L2-5 spinal segments showed that mammary rat metastasis tumor cells-1 injection induced phosphorylation of the GluN1 subunit of the N-methyl-D-aspartate receptor, indicative of receptor activation, and this was reduced by saracatinib.	saracatinib	335-346	glutamate ionotropic receptor NMDA type subunit 1	Rattus norvegicus	224-229
26474384-6	2015	Complete inhibition of T24 aggregate dispersal, however, is not achieved with any single agent, although partial inhibition was observed with 10 muM of the Src inhibitor, AZD-0530.	saracatinib	171-179	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	156-159
26493492-2	2016	Saracatinib potently inhibits Fyn activation.	saracatinib	0-11	FYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	30-33
26383165-4	2015	Src kinase blockade with the small-molecule inhibitor saracatinib prevented the disorganized three-dimensional growth of ER(-) mammary epithelial cells in vitro and delayed the development of premalignant lesions and tumors in vivo in mouse models developing HER2(+) and ER(-) mammary tumors, extending tumor-free and overall survival.	saracatinib	54-65	Rous sarcoma oncogene	Mus musculus	0-3
26383165-4	2015	Src kinase blockade with the small-molecule inhibitor saracatinib prevented the disorganized three-dimensional growth of ER(-) mammary epithelial cells in vitro and delayed the development of premalignant lesions and tumors in vivo in mouse models developing HER2(+) and ER(-) mammary tumors, extending tumor-free and overall survival.	saracatinib	54-65	erb-b2 receptor tyrosine kinase 2	Mus musculus	259-263
26045172-8	2015	Furthermore, the Src inhibitor saracatinib effectively blocked AOPP-induced phosphorylation of Src, activation of ER stress, hypertrophy, and EMT in HK-2 cells.	saracatinib	31-42	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	17-20
26208525-8	2015	Saracatinib, an src kinase inhibitor, suppressed ERK1/2 phosphorylation and growth of LC-2/ad DR cells.	saracatinib	0-11	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	16-19
26208525-8	2015	Saracatinib, an src kinase inhibitor, suppressed ERK1/2 phosphorylation and growth of LC-2/ad DR cells.	saracatinib	0-11	mitogen-activated protein kinase 3	Homo sapiens	49-55
26325669-3	2015	To better define the molecular targets of the Src TKIs saracatinib, dasatinib and bosutinib, we used a variety of in vitro/in vivo studies.	saracatinib	55-66	Rous sarcoma oncogene	Mus musculus	46-49
26325669-5	2015	However, in live cells only saracatinib efficiently reduced EGFR activation, while dasatinib was the most effective agent in inhibiting Src TK.	saracatinib	28-39	epidermal growth factor receptor	Mus musculus	60-64
26325669-7	2015	We then identified the most effective drug combinations to overcome resistance to EGFR inhibitors, both in vitro and in nude mice: in T790M EGFR erlotinib-resistant cells, saracatinib with the anti-EGFR mAb cetuximab; in Ras mutant erlotinib-resistant models, dasatinib with the MEK inhibitor selumetinib.	saracatinib	172-183	epidermal growth factor receptor	Mus musculus	82-86
26325669-7	2015	We then identified the most effective drug combinations to overcome resistance to EGFR inhibitors, both in vitro and in nude mice: in T790M EGFR erlotinib-resistant cells, saracatinib with the anti-EGFR mAb cetuximab; in Ras mutant erlotinib-resistant models, dasatinib with the MEK inhibitor selumetinib.	saracatinib	172-183	epidermal growth factor receptor	Mus musculus	140-144
26325669-7	2015	We then identified the most effective drug combinations to overcome resistance to EGFR inhibitors, both in vitro and in nude mice: in T790M EGFR erlotinib-resistant cells, saracatinib with the anti-EGFR mAb cetuximab; in Ras mutant erlotinib-resistant models, dasatinib with the MEK inhibitor selumetinib.	saracatinib	172-183	epidermal growth factor receptor	Mus musculus	140-144
26045172-8	2015	Furthermore, the Src inhibitor saracatinib effectively blocked AOPP-induced phosphorylation of Src, activation of ER stress, hypertrophy, and EMT in HK-2 cells.	saracatinib	31-42	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	95-98
26357463-10	2015	Src inhibitors, including PP2, PP1, Saracatinib, and Quercetin, partially inhibited LPS-induced phosphorylation of Cav-1.	saracatinib	36-47	SRC proto-oncogene, non-receptor tyrosine kinase	Rattus norvegicus	0-3
26357463-10	2015	Src inhibitors, including PP2, PP1, Saracatinib, and Quercetin, partially inhibited LPS-induced phosphorylation of Cav-1.	saracatinib	36-47	caveolin 1	Rattus norvegicus	115-120
26062928-3	2015	Saracatinib (AZD0530) is a novel selective oral Src kinase inhibitor.	saracatinib	0-11	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	48-51
26062928-3	2015	Saracatinib (AZD0530) is a novel selective oral Src kinase inhibitor.	saracatinib	13-20	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	48-51
26062928-15	2015	CONCLUSION: Saracatinib is a novel oral Src kinase inhibitor that was well tolerated but failed to meet its primary endpoint of improvement in 4 month progression-free survival as a single agent in previously treated metastatic colorectal cancer patients.	saracatinib	12-23	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	40-43
26009269-0	2015	A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies.	saracatinib	20-31	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	45-48
25820822-10	2015	Treatment of lung cancer cells with Src inhibitor saracatinib abrogates AFB1-induced IRS2 accumulation.	saracatinib	50-61	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	36-39
25820822-10	2015	Treatment of lung cancer cells with Src inhibitor saracatinib abrogates AFB1-induced IRS2 accumulation.	saracatinib	50-61	insulin receptor substrate 2	Homo sapiens	85-89
26170970-10	2015	Furthermore, the Src inhibitor, saracatinib, is currently in clinical trials for the treatment of a variety of solid tumors, including breast and lung cancers.	saracatinib	32-43	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	17-20
26009269-2	2015	Src plays a role in normal thymic epithelial maturation, and its inhibition with the oral compound saracatinib was postulated to be effective in controlling thymic malignancy.	saracatinib	99-110	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	0-3
26009269-12	2015	CONCLUSION: Src inhibition by saracatinib did not produce any radiographic responses, though some patients did experience stable disease.	saracatinib	30-41	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	12-15
25874001-5	2015	Herein, we present a Phase Ib trial of the repurposed investigational drug AZD0530, a Src family kinase inhibitor specific for Fyn and Src kinase, for the treatment of patients with mild-to-moderate AD.	saracatinib	75-82	FYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	86-89
25707991-9	2015	RESULTS: AZD0530 potently inhibits Fyn and prevents both Asso-induced Fyn signaling and downstream phosphorylation of the AD risk gene product Pyk2, and of NR2B Glu receptors in brain slices.	saracatinib	9-16	Fyn proto-oncogene	Mus musculus	35-38
25707991-9	2015	RESULTS: AZD0530 potently inhibits Fyn and prevents both Asso-induced Fyn signaling and downstream phosphorylation of the AD risk gene product Pyk2, and of NR2B Glu receptors in brain slices.	saracatinib	9-16	Fyn proto-oncogene	Mus musculus	70-73
25707991-9	2015	RESULTS: AZD0530 potently inhibits Fyn and prevents both Asso-induced Fyn signaling and downstream phosphorylation of the AD risk gene product Pyk2, and of NR2B Glu receptors in brain slices.	saracatinib	9-16	PTK2 protein tyrosine kinase 2 beta	Mus musculus	143-147
25707991-9	2015	RESULTS: AZD0530 potently inhibits Fyn and prevents both Asso-induced Fyn signaling and downstream phosphorylation of the AD risk gene product Pyk2, and of NR2B Glu receptors in brain slices.	saracatinib	9-16	glutamate receptor, ionotropic, NMDA2B (epsilon 2)	Mus musculus	156-160
25707991-10	2015	After 4 weeks of treatment, AZD0530 dosing of APP/PS1 transgenic mice fully rescues spatial memory deficits and synaptic depletion, without altering APP or Ass metabolism.	saracatinib	28-35	presenilin 1	Mus musculus	50-53
25707991-11	2015	AZD0530 treatment also reduces microglial activation in APP/PS1 mice, and rescues Tau phosphorylation and deposition abnormalities in APP/PS1/Tau transgenic mice.	saracatinib	0-7	presenilin 1	Mus musculus	60-63
25707991-11	2015	AZD0530 treatment also reduces microglial activation in APP/PS1 mice, and rescues Tau phosphorylation and deposition abnormalities in APP/PS1/Tau transgenic mice.	saracatinib	0-7	presenilin 1	Mus musculus	138-141
25874001-5	2015	Herein, we present a Phase Ib trial of the repurposed investigational drug AZD0530, a Src family kinase inhibitor specific for Fyn and Src kinase, for the treatment of patients with mild-to-moderate AD.	saracatinib	75-82	FYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	127-130
25662515-12	2015	The Src and BCR-Abl inhibitors saracatinib and AZD0424, along with the previous four drugs, are in clinical trials for a variety of solid tumors including breast and lung cancers.	saracatinib	31-42	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	4-7
25662515-12	2015	The Src and BCR-Abl inhibitors saracatinib and AZD0424, along with the previous four drugs, are in clinical trials for a variety of solid tumors including breast and lung cancers.	saracatinib	31-42	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	12-19
25070546-1	2014	BACKGROUND: We investigated whether the Src inhibitor saracatinib (AZD0530) improved efficacy of weekly paclitaxel in platinum-resistant ovarian cancer.	saracatinib	54-65	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	40-43
25338626-9	2015	The combination of bortezomib and saracatinib, a Src inhibitor, synergistically induced hepatoma cell apoptosis.	saracatinib	34-45	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	49-52
25070546-1	2014	BACKGROUND: We investigated whether the Src inhibitor saracatinib (AZD0530) improved efficacy of weekly paclitaxel in platinum-resistant ovarian cancer.	saracatinib	67-74	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	40-43
25226534-8	2014	Moreover, combination of SP600125 and the Src inhibitor saracatinib synergistically inhibits cell proliferation.	saracatinib	56-67	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	42-45
25047515-4	2014	The Src kinase inhibitor AZD0530 (saracatinib) blocked TGF-beta1-induced Src kinase activation in a dose-dependent manner.	saracatinib	25-32	transforming growth factor, beta 1	Mus musculus	55-64
25047515-4	2014	The Src kinase inhibitor AZD0530 (saracatinib) blocked TGF-beta1-induced Src kinase activation in a dose-dependent manner.	saracatinib	34-45	transforming growth factor, beta 1	Mus musculus	55-64
25047515-6	2014	In addition, the induced expression of collagen and fibronectin and three-dimensional collagen gel contraction were also significantly inhibited in AZD0530-treated fibroblasts.	saracatinib	148-155	fibronectin 1	Mus musculus	52-63
25047515-9	2014	Furthermore, the total fibrotic area and expression of alpha-SMA and ECM proteins were significantly decreased in lungs of AZD0530-treated mice.	saracatinib	123-130	actin alpha 2, smooth muscle, aorta	Mus musculus	55-64
25108485-6	2014	JAR and JEG-3 cells were treated with hCG, specific c-Src inhibitor saracatinib and PP2, and PKA specific inhibitor, PKI.	saracatinib	68-79	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	52-57
25108485-10	2014	Inhibition of c-Src activity in JAR and JEG-3 cells by saracatinib leaded to a decrease in the rate of cell growth and cell migration/invasion ability.	saracatinib	55-66	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	14-19
24828915-3	2014	Here, we report the development of a small molecule probe of Src through conjugation of BODIPY to two well-established dual Src-Abl kinase inhibitors, dasatinib and saracatinib.	saracatinib	165-176	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	61-64
25114223-5	2014	This approach identified a number of kinase inhibitors that robustly up-regulate IL-10 production including the Food and Drug Administration (FDA)-approved drugs dasatinib, bosutinib, and saracatinib that target ABL, SRC-family, and numerous other kinases.	saracatinib	188-199	interleukin 10	Homo sapiens	81-86
25114223-5	2014	This approach identified a number of kinase inhibitors that robustly up-regulate IL-10 production including the Food and Drug Administration (FDA)-approved drugs dasatinib, bosutinib, and saracatinib that target ABL, SRC-family, and numerous other kinases.	saracatinib	188-199	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	212-215
25114223-5	2014	This approach identified a number of kinase inhibitors that robustly up-regulate IL-10 production including the Food and Drug Administration (FDA)-approved drugs dasatinib, bosutinib, and saracatinib that target ABL, SRC-family, and numerous other kinases.	saracatinib	188-199	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	217-220
24968896-3	2014	Since Src is frequently activated in ovarian cancers, we investigated whether combined Src and ER blockade by saracatinib and fulvestrant would circumvent anti-estrogen resistance.	saracatinib	110-121	estrogen receptor 1	Homo sapiens	95-97
24968896-9	2014	Combined saracatinib and fulvestrant increased p27 and inhibited cell cycle progression.	saracatinib	9-20	interferon alpha inducible protein 27	Homo sapiens	47-50
24968896-11	2014	Saracatinib facilitated the therapeutic effects of fulvestrant by antagonizing the estrogen-mediated Src activation.	saracatinib	0-11	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	101-104
24713129-9	2014	However, lestaurtinib and saracatinib were identified as mechanism-based inhibitors of CYP3A.	saracatinib	26-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	87-92
24713129-11	2014	Inhibition of CYP2C8 by bosutinib was predicted to have no clinical relevance, whereas therapeutic lestaurtinib and saracatinib concentrations were predicted to increase the plasma exposure to CYP3A-dependent substrates by >=2.7-fold.	saracatinib	116-127	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	193-198
24828915-3	2014	Here, we report the development of a small molecule probe of Src through conjugation of BODIPY to two well-established dual Src-Abl kinase inhibitors, dasatinib and saracatinib.	saracatinib	165-176	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	124-127
24492292-0	2014	The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer.	saracatinib	78-89	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	64-67
24612061-7	2014	A Src inhibitor saracatinib impaired growth in cell lines that are insensitive to both Met and FGFR2 inhibitors.	saracatinib	16-27	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	2-5
24612061-8	2014	Saracatinib also effectively impaired peritoneal dissemination of Met-independent and FGFR2-independent SGC cells.	saracatinib	0-11	fibroblast growth factor receptor 2	Homo sapiens	86-91
24887236-8	2014	The selective small-molecule Src inhibitor saracatinib combined with lapatinib synergistically inhibited the proliferation, migration, and invasion of lapatinib-resistant cells.	saracatinib	43-54	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	29-32
24361364-13	2014	AZD0530 treatment demonstrated restoration of Cx43 comparable to PP1.	saracatinib	0-7	gap junction protein, alpha 1	Mus musculus	46-50
24111605-9	2014	AZD-0530 treatment blocked c-Src activation, decreased macrophage influx, and prevented airspace enlargement in the lungs of cigarette smoke-exposed mice.	saracatinib	0-8	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	27-32
24492292-0	2014	The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer.	saracatinib	78-89	erb-b2 receptor tyrosine kinase 2	Homo sapiens	114-119
24492292-2	2014	Here, we investigated the antitumor activity of the combination of trastuzumab and the SRC inhibitor saracatinib in ErbB2-overexpressing trastuzumab-resistant gastric cancer.	saracatinib	101-112	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	87-90
24492292-2	2014	Here, we investigated the antitumor activity of the combination of trastuzumab and the SRC inhibitor saracatinib in ErbB2-overexpressing trastuzumab-resistant gastric cancer.	saracatinib	101-112	erb-b2 receptor tyrosine kinase 2	Homo sapiens	116-121
24492292-5	2014	Our data demonstrated that trastuzumab plus saracatinib was much more potent than either agent alone in reducing the phosphorylation of ErbB3 and AKT in both NCI-N87 and NCI-N87R gastric cancer cell lines.	saracatinib	44-55	erb-b2 receptor tyrosine kinase 3	Homo sapiens	136-141
24492292-5	2014	Our data demonstrated that trastuzumab plus saracatinib was much more potent than either agent alone in reducing the phosphorylation of ErbB3 and AKT in both NCI-N87 and NCI-N87R gastric cancer cell lines.	saracatinib	44-55	AKT serine/threonine kinase 1	Homo sapiens	146-149
24492292-7	2014	Further data showed that combination therapy of trastuzumab with saracatinib resulted in a significant benefit over either agent alone in both NCI-N87 and NCI-N87R xenograft models, suggesting its potential use for treating ErbB2-overexpressing gastric cancer.	saracatinib	65-76	erb-b2 receptor tyrosine kinase 2	Homo sapiens	224-229
24169259-0	2014	A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium.	saracatinib	20-31	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	49-52
24495408-5	2014	We are currently enrolling patients in a phase Ib study of saracatinib (AZD0530), a small molecule inhibitor with high potency for Src and Fyn, for the treatment of AD.	saracatinib	59-70	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	131-134
24495408-5	2014	We are currently enrolling patients in a phase Ib study of saracatinib (AZD0530), a small molecule inhibitor with high potency for Src and Fyn, for the treatment of AD.	saracatinib	59-70	FYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	139-142
24495408-5	2014	We are currently enrolling patients in a phase Ib study of saracatinib (AZD0530), a small molecule inhibitor with high potency for Src and Fyn, for the treatment of AD.	saracatinib	72-79	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	131-134
24495408-5	2014	We are currently enrolling patients in a phase Ib study of saracatinib (AZD0530), a small molecule inhibitor with high potency for Src and Fyn, for the treatment of AD.	saracatinib	72-79	FYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	139-142
24200972-6	2014	Treatment with the Src inhibitor saracatinib in combination with lapatinib reduces AKT and ERK1/2 phosphorylation and restores the sensitivity of resistant cells to lapatinib.	saracatinib	33-44	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	19-22
24200972-6	2014	Treatment with the Src inhibitor saracatinib in combination with lapatinib reduces AKT and ERK1/2 phosphorylation and restores the sensitivity of resistant cells to lapatinib.	saracatinib	33-44	AKT serine/threonine kinase 1	Homo sapiens	83-86
24200972-6	2014	Treatment with the Src inhibitor saracatinib in combination with lapatinib reduces AKT and ERK1/2 phosphorylation and restores the sensitivity of resistant cells to lapatinib.	saracatinib	33-44	mitogen-activated protein kinase 3	Homo sapiens	91-97
24169259-2	2014	The activity of saracatinib, an orally available inhibitor of src kinases, was evaluated in patients with advanced, platinum-pretreated NSCLC.	saracatinib	16-27	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	62-65
23948603-11	2013	Given reports that SRC inhibitors can block Id1 expression, we tested the SRC inhibitor, AZD0530, and found that it inhibits the serum activation of Id1.	saracatinib	89-96	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	19-22
24201814-0	2013	An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530).	saracatinib	166-177	cadherin 1	Homo sapiens	116-126
24201814-0	2013	An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530).	saracatinib	179-186	cadherin 1	Homo sapiens	116-126
24201814-7	2013	A specific Src-kinase inhibitor, Saracatinib (AZD0530), restores E-cadherin expression in Intermediate M cells in in vitro and in vivo models and abrogates spheroidogenesis.	saracatinib	33-44	cadherin 1	Homo sapiens	65-75
24201814-7	2013	A specific Src-kinase inhibitor, Saracatinib (AZD0530), restores E-cadherin expression in Intermediate M cells in in vitro and in vivo models and abrogates spheroidogenesis.	saracatinib	46-53	cadherin 1	Homo sapiens	65-75
23948603-13	2013	Rather, we show that AZD0530 directly inhibits the BMP type I receptors.	saracatinib	21-28	bone morphogenetic protein 1	Homo sapiens	51-54
23948603-11	2013	Given reports that SRC inhibitors can block Id1 expression, we tested the SRC inhibitor, AZD0530, and found that it inhibits the serum activation of Id1.	saracatinib	89-96	inhibitor of DNA binding 1, HLH protein	Homo sapiens	44-47
23948603-11	2013	Given reports that SRC inhibitors can block Id1 expression, we tested the SRC inhibitor, AZD0530, and found that it inhibits the serum activation of Id1.	saracatinib	89-96	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	74-77
23948603-11	2013	Given reports that SRC inhibitors can block Id1 expression, we tested the SRC inhibitor, AZD0530, and found that it inhibits the serum activation of Id1.	saracatinib	89-96	inhibitor of DNA binding 1, HLH protein	Homo sapiens	149-152
22415795-0	2013	First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours.	saracatinib	91-102	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	70-73
22415795-0	2013	First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours.	saracatinib	104-111	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	70-73
22415795-1	2013	BACKGROUND: Saracatinib (AZD0530) is a selective, oral Src inhibitor that has demonstrated antitumour activity in preclinical studies.	saracatinib	12-23	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	55-58
22415795-1	2013	BACKGROUND: Saracatinib (AZD0530) is a selective, oral Src inhibitor that has demonstrated antitumour activity in preclinical studies.	saracatinib	25-32	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	55-58
22623106-0	2013	Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo.	saracatinib	0-11	ATP binding cassette subfamily B member 1	Homo sapiens	47-52
22310287-9	2013	This mode of invasion is dependent on integrin-mediated adhesion, and because SRC kinases are the main regulators of this process, the SRC kinase inhibitor, saracatinib (AZD0530), completely abolished the MEK inhibitor-induced invasion.	saracatinib	157-168	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	78-81
22310287-9	2013	This mode of invasion is dependent on integrin-mediated adhesion, and because SRC kinases are the main regulators of this process, the SRC kinase inhibitor, saracatinib (AZD0530), completely abolished the MEK inhibitor-induced invasion.	saracatinib	157-168	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	135-138
22310287-9	2013	This mode of invasion is dependent on integrin-mediated adhesion, and because SRC kinases are the main regulators of this process, the SRC kinase inhibitor, saracatinib (AZD0530), completely abolished the MEK inhibitor-induced invasion.	saracatinib	157-168	mitogen-activated protein kinase kinase 7	Homo sapiens	205-208
22310287-9	2013	This mode of invasion is dependent on integrin-mediated adhesion, and because SRC kinases are the main regulators of this process, the SRC kinase inhibitor, saracatinib (AZD0530), completely abolished the MEK inhibitor-induced invasion.	saracatinib	170-177	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	78-81
22310287-9	2013	This mode of invasion is dependent on integrin-mediated adhesion, and because SRC kinases are the main regulators of this process, the SRC kinase inhibitor, saracatinib (AZD0530), completely abolished the MEK inhibitor-induced invasion.	saracatinib	170-177	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	135-138
22310287-9	2013	This mode of invasion is dependent on integrin-mediated adhesion, and because SRC kinases are the main regulators of this process, the SRC kinase inhibitor, saracatinib (AZD0530), completely abolished the MEK inhibitor-induced invasion.	saracatinib	170-177	mitogen-activated protein kinase kinase 7	Homo sapiens	205-208
22310287-10	2013	Moreover, the combination of saracatinib and selumetinib effectively suppressed the growth and invasion of melanoma cells in a 3D environment, suggesting that combined inhibition of MEK and SRC is a promising approach to improve the efficacy of targeting the ERK/MAP kinase pathway in melanoma.	saracatinib	29-40	mitogen-activated protein kinase kinase 7	Homo sapiens	182-185
22310287-10	2013	Moreover, the combination of saracatinib and selumetinib effectively suppressed the growth and invasion of melanoma cells in a 3D environment, suggesting that combined inhibition of MEK and SRC is a promising approach to improve the efficacy of targeting the ERK/MAP kinase pathway in melanoma.	saracatinib	29-40	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	190-193
22310287-10	2013	Moreover, the combination of saracatinib and selumetinib effectively suppressed the growth and invasion of melanoma cells in a 3D environment, suggesting that combined inhibition of MEK and SRC is a promising approach to improve the efficacy of targeting the ERK/MAP kinase pathway in melanoma.	saracatinib	29-40	mitogen-activated protein kinase 1	Homo sapiens	259-262
22623106-0	2013	Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo.	saracatinib	13-20	ATP binding cassette subfamily B member 1	Homo sapiens	47-52
22623106-1	2013	Saracatinib, a highly selective, dual Src/Abl kinase inhibitor, is currently in a Phase II clinical trial for the treatment of ovarian cancer.	saracatinib	0-11	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	38-41
22623106-3	2013	Our results showed that saracatinib significantly enhanced the cytotoxicity of ABCB1 substrate drugs in ABCB1 overexpressing HeLa/v200, MCF-7/adr and HEK293/ABCB1 cells, an effect that was stronger than that of gefitinib, whereas it had no effect on the cytotoxicity of the substrates in ABCC1 overexpressing HL-60/adr cells and its parental sensitive cells.	saracatinib	24-35	ATP binding cassette subfamily B member 1	Homo sapiens	79-84
22623106-3	2013	Our results showed that saracatinib significantly enhanced the cytotoxicity of ABCB1 substrate drugs in ABCB1 overexpressing HeLa/v200, MCF-7/adr and HEK293/ABCB1 cells, an effect that was stronger than that of gefitinib, whereas it had no effect on the cytotoxicity of the substrates in ABCC1 overexpressing HL-60/adr cells and its parental sensitive cells.	saracatinib	24-35	ATP binding cassette subfamily B member 1	Homo sapiens	104-109
22623106-3	2013	Our results showed that saracatinib significantly enhanced the cytotoxicity of ABCB1 substrate drugs in ABCB1 overexpressing HeLa/v200, MCF-7/adr and HEK293/ABCB1 cells, an effect that was stronger than that of gefitinib, whereas it had no effect on the cytotoxicity of the substrates in ABCC1 overexpressing HL-60/adr cells and its parental sensitive cells.	saracatinib	24-35	ATP binding cassette subfamily B member 1	Homo sapiens	104-109
22623106-3	2013	Our results showed that saracatinib significantly enhanced the cytotoxicity of ABCB1 substrate drugs in ABCB1 overexpressing HeLa/v200, MCF-7/adr and HEK293/ABCB1 cells, an effect that was stronger than that of gefitinib, whereas it had no effect on the cytotoxicity of the substrates in ABCC1 overexpressing HL-60/adr cells and its parental sensitive cells.	saracatinib	24-35	ATP binding cassette subfamily C member 1	Homo sapiens	288-293
22623106-5	2013	Furthermore, saracatinib stimulated the ATPase activity and inhibited photolabeling of ABCB1 with [(125)I]-iodoarylazidoprazosin in a concentration-dependent manner.	saracatinib	13-24	ATP binding cassette subfamily B member 1	Homo sapiens	87-92
22623106-6	2013	In addition, the homology modeling predicted the binding conformation of saracatinib within the large hydrophobic drug-binding cavity of human ABCB1.	saracatinib	73-84	ATP binding cassette subfamily B member 1	Homo sapiens	143-148
22623106-8	2013	Importantly, saracatinib significantly enhanced the effect of paclitaxel against ABCB1-overexpressing HeLa/v200 cancer cell xenografts in nude mice.	saracatinib	13-24	ATP binding cassette subfamily B member 1	Homo sapiens	81-86
22623106-9	2013	In conclusion, saracatinib reverses ABCB1-mediated MDR in vitro and in vivo by directly inhibiting ABCB1 transport function, without altering ABCB1 expression or AKT phosphorylation.	saracatinib	15-26	ATP binding cassette subfamily B member 1	Homo sapiens	36-41
22623106-9	2013	In conclusion, saracatinib reverses ABCB1-mediated MDR in vitro and in vivo by directly inhibiting ABCB1 transport function, without altering ABCB1 expression or AKT phosphorylation.	saracatinib	15-26	ATP binding cassette subfamily B member 1	Homo sapiens	99-104
22623106-9	2013	In conclusion, saracatinib reverses ABCB1-mediated MDR in vitro and in vivo by directly inhibiting ABCB1 transport function, without altering ABCB1 expression or AKT phosphorylation.	saracatinib	15-26	ATP binding cassette subfamily B member 1	Homo sapiens	99-104
23144237-0	2013	Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.	saracatinib	22-33	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	47-52
23144237-0	2013	Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.	saracatinib	35-42	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	47-52
23144237-4	2013	We evaluated the antitumor effect of a c-Src/Abl kinase inhibitor, saracatinib (AZD0530), alone or combined with chemotherapeutic agents in gastric cancer cell lines and a NCI-N87 xenograft model.	saracatinib	67-78	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	39-44
23144237-6	2013	Saracatinib blocked the Src/FAK, HER family, and oncogenic signaling pathways, and it induced G(1) arrest and apoptosis in SNU216 and NCI-N87 cells.	saracatinib	0-11	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	24-27
23144237-6	2013	Saracatinib blocked the Src/FAK, HER family, and oncogenic signaling pathways, and it induced G(1) arrest and apoptosis in SNU216 and NCI-N87 cells.	saracatinib	0-11	protein tyrosine kinase 2	Homo sapiens	28-31
23144237-8	2013	Knockdown of Bim using siRNA decreased apoptosis induced by treatment with saracatinib, suggesting that Bim has an important role in saracatinib-induced apoptosis.	saracatinib	75-86	BCL2 like 11	Homo sapiens	13-16
23144237-8	2013	Knockdown of Bim using siRNA decreased apoptosis induced by treatment with saracatinib, suggesting that Bim has an important role in saracatinib-induced apoptosis.	saracatinib	75-86	BCL2 like 11	Homo sapiens	104-107
23144237-8	2013	Knockdown of Bim using siRNA decreased apoptosis induced by treatment with saracatinib, suggesting that Bim has an important role in saracatinib-induced apoptosis.	saracatinib	133-144	BCL2 like 11	Homo sapiens	13-16
23144237-8	2013	Knockdown of Bim using siRNA decreased apoptosis induced by treatment with saracatinib, suggesting that Bim has an important role in saracatinib-induced apoptosis.	saracatinib	133-144	BCL2 like 11	Homo sapiens	104-107
23144237-9	2013	Saracatinib enhanced the effects of lapatinib, an EGFR/HER2 dual inhibitor, in SNU216 and NCI-N87 cells.	saracatinib	0-11	epidermal growth factor receptor	Homo sapiens	50-54
23144237-9	2013	Saracatinib enhanced the effects of lapatinib, an EGFR/HER2 dual inhibitor, in SNU216 and NCI-N87 cells.	saracatinib	0-11	erb-b2 receptor tyrosine kinase 2	Homo sapiens	55-59
23144237-12	2013	These data indicate that the inhibition of Src kinase activity by saracatinib alone or in combination with other agents can be a strategy to target gastric cancer.	saracatinib	66-77	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	43-46
23342270-0	2012	Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer.	saracatinib	92-103	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	113-116
22896656-0	2012	Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.	saracatinib	20-31	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	0-3
22896656-0	2012	Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.	saracatinib	20-31	estrogen receptor 1	Homo sapiens	67-69
22896656-4	2012	Because Src is activated in most ovarian cancers, we investigated whether combined Src and ER blockade by saracatinib and fulvestrant would circumvent antiestrogen resistance.	saracatinib	106-117	estrogen receptor 1	Homo sapiens	91-93
22896656-11	2012	While each alone had little effect, combined saracatinib and fulvestrant increased p27 and inhibited cyclin E-Cdk2 and cell-cycle progression.	saracatinib	45-56	interferon alpha inducible protein 27	Homo sapiens	83-86
22896656-12	2012	Saracatinib also impaired induction of ER-target genes c-Myc and FOSL1; this was greatest with dual therapy.	saracatinib	0-11	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	55-60
22896656-12	2012	Saracatinib also impaired induction of ER-target genes c-Myc and FOSL1; this was greatest with dual therapy.	saracatinib	0-11	FOS like 1, AP-1 transcription factor subunit	Homo sapiens	65-70
22896656-14	2012	CONCLUSIONS: Saracatinib augments effects of fulvestrant by opposing estrogen-mediated Src activation and target gene expression, increasing cell-cycle arrest, and impairing survival, all of which would oppose antiestrogen resistance in these ER+ ovarian cancer models.	saracatinib	13-24	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	87-90
23342270-1	2012	Src tyrosine kinases are overexpressed in pancreatic cancers, and the oral Src inhibitor saracatinib has shown antitumor activity in preclinical models of pancreas cancer.	saracatinib	89-100	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	75-78
21989836-0	2012	Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours.	saracatinib	120-131	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	106-109
22526632-5	2012	In the present studies, we have examined the ability of saracatinib, a dual-specific, orally available inhibitor of Src and Abl protein tyrosine kinases, to interfere with the establishment of lung metastases in mice by tumor cells introduced into the blood stream.	saracatinib	56-67	Rous sarcoma oncogene	Mus musculus	116-119
22249264-4	2012	Incubation of lung cancer cells with the Src inhibitor saracatinib led to the upregulation of several miRNAs including miR-29b, which was the most highly upregulated miRNA with predicted binding to the ID1 3"-untranslated region (UTR).	saracatinib	55-66	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	41-44
22249264-4	2012	Incubation of lung cancer cells with the Src inhibitor saracatinib led to the upregulation of several miRNAs including miR-29b, which was the most highly upregulated miRNA with predicted binding to the ID1 3"-untranslated region (UTR).	saracatinib	55-66	microRNA 29b-1	Homo sapiens	119-126
22249264-4	2012	Incubation of lung cancer cells with the Src inhibitor saracatinib led to the upregulation of several miRNAs including miR-29b, which was the most highly upregulated miRNA with predicted binding to the ID1 3"-untranslated region (UTR).	saracatinib	55-66	inhibitor of DNA binding 1, HLH protein	Homo sapiens	202-205
22249264-9	2012	Both, anti-miR-29b and ID1 overexpression diminished the effects of the Src inhibitors saracatinib and dasatinib on migration and invasion.	saracatinib	87-98	microRNA 29b-1	Homo sapiens	11-18
22249264-9	2012	Both, anti-miR-29b and ID1 overexpression diminished the effects of the Src inhibitors saracatinib and dasatinib on migration and invasion.	saracatinib	87-98	inhibitor of DNA binding 1, HLH protein	Homo sapiens	23-26
22249264-9	2012	Both, anti-miR-29b and ID1 overexpression diminished the effects of the Src inhibitors saracatinib and dasatinib on migration and invasion.	saracatinib	87-98	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	72-75
22249264-10	2012	Saracatinib and dasatinib decreased c-Myc transcriptional repression on miR-29b and led to increased ID1 protein levels, whereas forced expression of c-Myc repressed miR-29b and induced ID1.	saracatinib	0-11	microRNA 29b-1	Homo sapiens	72-79
22249264-10	2012	Saracatinib and dasatinib decreased c-Myc transcriptional repression on miR-29b and led to increased ID1 protein levels, whereas forced expression of c-Myc repressed miR-29b and induced ID1.	saracatinib	0-11	inhibitor of DNA binding 1, HLH protein	Homo sapiens	101-104
22526632-5	2012	In the present studies, we have examined the ability of saracatinib, a dual-specific, orally available inhibitor of Src and Abl protein tyrosine kinases, to interfere with the establishment of lung metastases in mice by tumor cells introduced into the blood stream.	saracatinib	56-67	c-abl oncogene 1, non-receptor tyrosine kinase	Mus musculus	124-127
22452946-0	2012	Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas.	saracatinib	36-47	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	22-25
22452946-0	2012	Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas.	saracatinib	49-57	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	22-25
22452946-3	2012	Among potential candidate molecules, we evaluated the nonreceptor tyrosine kinase Src, observing promising antitumor effects of its small-molecule inhibitor saracatinib in BTC preclinical models.	saracatinib	157-168	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	82-85
22452946-5	2012	Upon saracatinib treatment, the phosphorylation of Src and of its downstream transducers was evaluated in the BTC cell lines TFK-1, EGI-1, HuH28, and TGBC1-TKB.	saracatinib	5-16	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	51-54
22452946-9	2012	In cultured BTC cell lines, low-dose saracatinib counteracted the activation of Src and of its downstream effectors, increased the fraction of cells in G(0)-G(1) phase, and inhibited cell migration.	saracatinib	37-48	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	80-83
22452946-12	2012	Here, we provide a demonstration that the targeted inhibition of Src kinase by saracatinib is of therapeutic benefit in preclinical models of BTC.	saracatinib	79-90	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	65-68
21894461-5	2012	Inhibition of Src kinase activity using the inhibitors PP2 or saracatinib or using siRNA abrogates the preferential migration of the breast cancer cell lines in response to bone-derived cells.	saracatinib	62-73	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	14-17
21792888-5	2012	Activation of migration related components FAK, P130Cas and Paxillin were blocked by saracatinib at 0.05- to 3-muM concentrations.	saracatinib	85-96	BCAR1 scaffold protein, Cas family member	Homo sapiens	48-55
21792888-7	2012	Molecular studies in Caki-1 showed that saracatinib alone and in combination with sunitinib inhibited phosphorylation of the cell progression regulator c-Myc in a dose-dependent manner.	saracatinib	40-51	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	152-157
21792888-10	2012	HIF1-alpha expression in normoxic and hypoxic conditions in Caki-1 cells was inhibited by either saracatinib or sunitinib when administered alone, however, a greater reduction occurred when these compounds were given in combination.	saracatinib	97-108	hypoxia inducible factor 1 subunit alpha	Homo sapiens	0-10
22592211-7	2012	The Src tyrosine kinase inhibitors saracatinib and dasatinib were used to repress ID1 expression.	saracatinib	35-46	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	4-7
22592211-7	2012	The Src tyrosine kinase inhibitors saracatinib and dasatinib were used to repress ID1 expression.	saracatinib	35-46	inhibitor of DNA binding 1, HLH protein	Homo sapiens	82-85
22596237-3	2012	METHODS: First, in investigating imaging biomarkers of invasion, the response of orthotopic murine PC3 prostate xenografts to the Src inhibitor saracatinib was assessed using susceptibility contrast MRI.	saracatinib	144-155	chromobox 8	Mus musculus	99-102
22596237-3	2012	METHODS: First, in investigating imaging biomarkers of invasion, the response of orthotopic murine PC3 prostate xenografts to the Src inhibitor saracatinib was assessed using susceptibility contrast MRI.	saracatinib	144-155	Rous sarcoma oncogene	Mus musculus	130-133
22596237-5	2012	RESULTS: No significant differences in fractional blood volume (%), vessel calibre (mum), native T(1) (ms) or apparent water diffusion coefficient were determined, despite reduced expression of activated Fak and paxillin in the saracatinib cohort.	saracatinib	228-239	paxillin	Rattus norvegicus	212-220
21400081-0	2012	A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium.	saracatinib	45-56	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	24-27
21400081-0	2012	A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium.	saracatinib	58-65	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	24-27
21400081-2	2012	We evaluated the activity and safety of saracatinib an oral, anilinoquinazolone, non-receptor tyrosine kinase inhibitor targeting Src kinases, in patients with metastatic or locally advanced gastric carcinoma.	saracatinib	40-51	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	130-133
21894461-6	2012	Inhibition of Src activity with saracatinib does not have any significant effect on breast cancer cell invasion in the presence of bone-derived cells.	saracatinib	32-43	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	14-17
22553375-0	2012	Common PIK3CA mutants and a novel 3" UTR mutation are associated with increased sensitivity to saracatinib.	saracatinib	95-106	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	7-13
22553375-6	2012	Mutations in the PIK3CA were evaluated to examine the association between mutations in the PIK3CA gene and sensitivity to saracatinib.	saracatinib	122-133	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	91-97
22553375-7	2012	RESULTS: We have identified a subset of patients with a PIK3CA (exon 9 and 20) mutation with increased sensitivity to saracatinib.	saracatinib	118-129	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	56-62
22450814-5	2012	Saracatinib, a specific inhibitor of Src family kinases, administered at low doses during the expansion or contraction phases, increased CD62L(high)/CD44(high) central memory CD8(+) T cells and IFN-gamma production but suppressed immunity when added during the priming phase.	saracatinib	0-11	selectin, lymphocyte	Mus musculus	137-142
22450814-5	2012	Saracatinib, a specific inhibitor of Src family kinases, administered at low doses during the expansion or contraction phases, increased CD62L(high)/CD44(high) central memory CD8(+) T cells and IFN-gamma production but suppressed immunity when added during the priming phase.	saracatinib	0-11	CD44 antigen	Mus musculus	149-153
22450814-5	2012	Saracatinib, a specific inhibitor of Src family kinases, administered at low doses during the expansion or contraction phases, increased CD62L(high)/CD44(high) central memory CD8(+) T cells and IFN-gamma production but suppressed immunity when added during the priming phase.	saracatinib	0-11	interferon gamma	Mus musculus	194-203
22450814-6	2012	These effects by saracatinib were not accompanied by the expected decline of Src family kinases but were accompanied by Akt-mammalian target of rapamycin suppression and/or mediated via another pathway.	saracatinib	17-28	AKT serine/threonine kinase 1	Homo sapiens	120-123
22450814-6	2012	These effects by saracatinib were not accompanied by the expected decline of Src family kinases but were accompanied by Akt-mammalian target of rapamycin suppression and/or mediated via another pathway.	saracatinib	17-28	mechanistic target of rapamycin kinase	Homo sapiens	124-153
22326918-8	2012	In addition, we found that treatment with AZD-0530, a pharmacological Src inhibitor, reduced the regulatory effect of TRAF6 knockdown on VEGF promoter activity.	saracatinib	42-50	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	70-73
21170669-0	2012	A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer.	saracatinib	40-51	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	26-29
21170669-0	2012	A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer.	saracatinib	53-60	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	26-29
22326918-8	2012	In addition, we found that treatment with AZD-0530, a pharmacological Src inhibitor, reduced the regulatory effect of TRAF6 knockdown on VEGF promoter activity.	saracatinib	42-50	TNF receptor associated factor 6	Homo sapiens	118-123
22326918-8	2012	In addition, we found that treatment with AZD-0530, a pharmacological Src inhibitor, reduced the regulatory effect of TRAF6 knockdown on VEGF promoter activity.	saracatinib	42-50	vascular endothelial growth factor A	Homo sapiens	137-141
22471705-4	2012	There are currently four Src inhibitors (dasatinib, saracatinib, bosutinib, and KX01) in clinical development, and although there is a plethora of information on their activity in preclinical models their clinical efficacy has been disappointing.	saracatinib	52-63	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	25-28
22157722-5	2012	AZD0530 is a Src TKI, TSA is a histone deacetylase inhibitor, and ABT-263 is a Bcl-2 inhibitor.	saracatinib	0-7	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	13-16
22369552-6	2012	To confirm that TGF-beta3 plays a role in epithelial barrier function, a selective Src family kinase inhibitor saracatinib (AZD0530) was added to cells treated with active TGF-beta3.	saracatinib	111-122	transforming growth factor beta 3	Homo sapiens	16-25
21863025-8	2011	In addition, CR-1 significantly increased the invasive ability of melanoma cells that was prevented by treatment with either the ALK4 inhibitor SB-431542 or the c-Src inhibitor saracatinib (AZD0530).	saracatinib	177-188	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	161-166
21994334-8	2011	Importantly, LHBs-induced cellular proliferation and tumor formation were reversed by administration of the Src inhibitor saracatinib.	saracatinib	122-133	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	108-111
21499296-8	2011	Finally, the combination of lapatinib and the Src inhibitor AZD0530 was more effective than lapatinib alone at inhibiting pAkt and growth of established HER2-positive BT-474 xenografts in athymic mice.	saracatinib	60-67	Rous sarcoma oncogene	Mus musculus	46-49
21499296-8	2011	Finally, the combination of lapatinib and the Src inhibitor AZD0530 was more effective than lapatinib alone at inhibiting pAkt and growth of established HER2-positive BT-474 xenografts in athymic mice.	saracatinib	60-67	erb-b2 receptor tyrosine kinase 2	Mus musculus	153-157
21729667-0	2011	Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer.	saracatinib	18-29	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	49-52
21729667-0	2011	Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer.	saracatinib	31-38	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	49-52
21729667-2	2011	Saracatinib is an oral tyrosine kinase inhibitor (TKI) selective for SRC.	saracatinib	0-11	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	69-72
21729667-3	2011	We performed this trial to evaluate the efficacy and safety of saracatinib monotherapy in patients with estrogen receptor (ER)(-) and progesterone receptor (PR)(-) metastatic breast cancer (MBC).	saracatinib	63-74	progesterone receptor	Homo sapiens	134-155
21863025-8	2011	In addition, CR-1 significantly increased the invasive ability of melanoma cells that was prevented by treatment with either the ALK4 inhibitor SB-431542 or the c-Src inhibitor saracatinib (AZD0530).	saracatinib	190-197	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	161-166
20630825-2	2010	Several Src inhibitors, including dasatinib, saracatinib, bosutinib, and KX2-391, are currently being investigated in clinical trials.	saracatinib	45-56	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	8-11
20551056-6	2010	Saracatinib resembles the pharmacophore of known organic cation transporter (OCT) inhibitors and reduced oxaliplatin efficacy maximally in cells overexpressing OCT2.	saracatinib	0-11	solute carrier family 22 member 2	Homo sapiens	160-164
20551056-7	2010	These data suggest that oxaliplatin uptake in CRC is attenuated by saracatinib via inhibition of OCT2, a potential consideration for the clinical development of this SFK inhibitor.	saracatinib	67-78	solute carrier family 22 member 2	Homo sapiens	97-101
21642769-3	2011	In transformed cells, CHK1 inhibitor -induced activation of ERK1/2 was dependent upon activation of SRC family non-receptor tyrosine kinases as judged by use of multiple SRC kinase inhibitors (PP2, Dasatinib; AZD0530), use of SRC/FYN/YES deleted transformed fibroblasts or by expression of dominant negative SRC.	saracatinib	209-216	checkpoint kinase 1	Homo sapiens	22-26
21642769-3	2011	In transformed cells, CHK1 inhibitor -induced activation of ERK1/2 was dependent upon activation of SRC family non-receptor tyrosine kinases as judged by use of multiple SRC kinase inhibitors (PP2, Dasatinib; AZD0530), use of SRC/FYN/YES deleted transformed fibroblasts or by expression of dominant negative SRC.	saracatinib	209-216	mitogen-activated protein kinase 3	Homo sapiens	60-66
21642769-3	2011	In transformed cells, CHK1 inhibitor -induced activation of ERK1/2 was dependent upon activation of SRC family non-receptor tyrosine kinases as judged by use of multiple SRC kinase inhibitors (PP2, Dasatinib; AZD0530), use of SRC/FYN/YES deleted transformed fibroblasts or by expression of dominant negative SRC.	saracatinib	209-216	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	100-103
20669046-3	2011	In this article, we show that treatment with the Src-inhibitor saracatinib (AZD0530) together with ER-blocking drugs increased breast cancer cell cycle arrest via p27.	saracatinib	63-74	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	49-52
20669046-3	2011	In this article, we show that treatment with the Src-inhibitor saracatinib (AZD0530) together with ER-blocking drugs increased breast cancer cell cycle arrest via p27.	saracatinib	63-74	estrogen receptor 1	Homo sapiens	99-101
20669046-3	2011	In this article, we show that treatment with the Src-inhibitor saracatinib (AZD0530) together with ER-blocking drugs increased breast cancer cell cycle arrest via p27.	saracatinib	63-74	zinc ribbon domain containing 2	Homo sapiens	163-166
20669046-3	2011	In this article, we show that treatment with the Src-inhibitor saracatinib (AZD0530) together with ER-blocking drugs increased breast cancer cell cycle arrest via p27.	saracatinib	76-83	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	49-52
20669046-3	2011	In this article, we show that treatment with the Src-inhibitor saracatinib (AZD0530) together with ER-blocking drugs increased breast cancer cell cycle arrest via p27.	saracatinib	76-83	zinc ribbon domain containing 2	Homo sapiens	163-166
20669046-4	2011	Saracatinib and fulvestrant together more effectively increased p27, reduced Ki67, and impaired MDA-MB-361 xenograft tumor growth in vivo than either of the drugs alone.	saracatinib	0-11	zinc ribbon domain containing 2	Homo sapiens	64-67
20669046-6	2011	Since combined ER and Src inhibition delays development of resistance in vivo, these data support further clinical investigation of saracatinib in combination with fulvestrant for women with ER-positive breast cancer.	saracatinib	132-143	estrogen receptor 1	Homo sapiens	15-17
20669046-6	2011	Since combined ER and Src inhibition delays development of resistance in vivo, these data support further clinical investigation of saracatinib in combination with fulvestrant for women with ER-positive breast cancer.	saracatinib	132-143	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	22-25
20669046-6	2011	Since combined ER and Src inhibition delays development of resistance in vivo, these data support further clinical investigation of saracatinib in combination with fulvestrant for women with ER-positive breast cancer.	saracatinib	132-143	estrogen receptor 1	Homo sapiens	191-193
20669046-7	2011	Proteomic analysis revealed striking bypass activation of the mTOR pathway in saracatinib-resistant tumors.	saracatinib	78-89	mechanistic target of rapamycin kinase	Homo sapiens	62-66
20669046-8	2011	mTORC1 activation also arose following long-term culture of ER-positive breast cancer lines in the presence of saracatinib.	saracatinib	111-122	CREB regulated transcription coactivator 1	Mus musculus	0-6
20669046-8	2011	mTORC1 activation also arose following long-term culture of ER-positive breast cancer lines in the presence of saracatinib.	saracatinib	111-122	estrogen receptor 1	Homo sapiens	60-62
20669046-10	2011	The use of mTOR kinase inhibitors with saracatinib may subvert drug resistance and prove to be more effective than saracatinib alone.	saracatinib	39-50	mechanistic target of rapamycin kinase	Homo sapiens	11-15
20669046-10	2011	The use of mTOR kinase inhibitors with saracatinib may subvert drug resistance and prove to be more effective than saracatinib alone.	saracatinib	115-126	mechanistic target of rapamycin kinase	Homo sapiens	11-15
21461172-10	2011	An experimental Src kinase inhibitor, AZD0530, almost completely antagonized the TMZ-induced modulation in caveolin-1 expression.	saracatinib	38-45	caveolin 1	Homo sapiens	107-117
21156787-7	2011	The treatment with Src inhibitors, such as PP2, dasatinib, and saracatinib, also suppressed the growth of A549 cells.	saracatinib	63-74	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	19-22
21115886-2	2010	The aim of the present studies was to examine the impact of an Src inhibitor (saracatinib) on a highly metastatic murine sarcoma cell line (KHT).	saracatinib	78-89	Rous sarcoma oncogene	Mus musculus	63-66
21115886-6	2010	RESULTS: Saracatinib inhibited major pathways in the metastatic cascade in vitro, including Src and FAK activation.	saracatinib	9-20	Rous sarcoma oncogene	Mus musculus	92-95
21115886-6	2010	RESULTS: Saracatinib inhibited major pathways in the metastatic cascade in vitro, including Src and FAK activation.	saracatinib	9-20	PTK2 protein tyrosine kinase 2	Mus musculus	100-103
21115886-9	2010	CONCLUSION: These findings suggest that Src inhibition by saracatinib may reduce the metastatic activity of tumor cells.	saracatinib	58-69	Rous sarcoma oncogene	Mus musculus	40-43
20805299-0	2010	Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.	saracatinib	74-85	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	52-55
20805299-1	2010	PURPOSE: This dose-escalation study evaluated the safety, tolerability, and pharmacokinetics (PK) of the oral Src inhibitor saracatinib (AZD0530) in patients with advanced solid malignancies.	saracatinib	124-135	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	110-113
20805299-1	2010	PURPOSE: This dose-escalation study evaluated the safety, tolerability, and pharmacokinetics (PK) of the oral Src inhibitor saracatinib (AZD0530) in patients with advanced solid malignancies.	saracatinib	137-144	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	110-113
20805299-2	2010	Tumor biopsy samples were taken to investigate the effect of saracatinib on Src activity in tumors.	saracatinib	61-72	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	76-79
20805299-10	2010	Tumor Src activity was reduced following saracatinib treatment.	saracatinib	41-52	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	6-9
20557276-6	2010	SKI-606 and AZD0530 are two other important dual Src/Abl inhibitors extensively tested in animal models and in clinical trials, but not entered into therapy yet.	saracatinib	12-19	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	49-52
20557276-6	2010	SKI-606 and AZD0530 are two other important dual Src/Abl inhibitors extensively tested in animal models and in clinical trials, but not entered into therapy yet.	saracatinib	12-19	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	53-56
20683035-1	2010	BACKGROUND: Saracatinib (AZD0530), a potent Src inhibitor, is a subject of current evaluation as an anticancer therapy.	saracatinib	12-23	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	44-47
20683035-1	2010	BACKGROUND: Saracatinib (AZD0530), a potent Src inhibitor, is a subject of current evaluation as an anticancer therapy.	saracatinib	25-32	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	44-47
20811583-5	2010	Previously, the authors reported that Src inhibitors such as saracatinib and PP2 caused G1 growth arrest and diminished invasiveness in prostate cancer cells but rarely apoptosis.	saracatinib	61-72	Rous sarcoma oncogene	Mus musculus	38-41
20484016-0	2010	Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.	saracatinib	51-62	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	23-26
20484016-5	2010	We hypothesized that inhibiting Src activity with the specific Src family kinase inhibitor saracatinib (AZD0530) would inhibit tumor cell growth and osteoclast differentiation in the tumor-bone interface, thus providing a new approach for advanced prostate cancer.	saracatinib	91-102	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	32-35
20484016-5	2010	We hypothesized that inhibiting Src activity with the specific Src family kinase inhibitor saracatinib (AZD0530) would inhibit tumor cell growth and osteoclast differentiation in the tumor-bone interface, thus providing a new approach for advanced prostate cancer.	saracatinib	91-102	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	63-66
20484016-5	2010	We hypothesized that inhibiting Src activity with the specific Src family kinase inhibitor saracatinib (AZD0530) would inhibit tumor cell growth and osteoclast differentiation in the tumor-bone interface, thus providing a new approach for advanced prostate cancer.	saracatinib	104-111	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	32-35
20484016-5	2010	We hypothesized that inhibiting Src activity with the specific Src family kinase inhibitor saracatinib (AZD0530) would inhibit tumor cell growth and osteoclast differentiation in the tumor-bone interface, thus providing a new approach for advanced prostate cancer.	saracatinib	104-111	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	63-66
20484016-7	2010	Phosphorylation of Src, focal adhesion kinase, and P38 kinases was inhibited by saracatinib at the submicromolar range.	saracatinib	80-91	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	19-22
20484016-7	2010	Phosphorylation of Src, focal adhesion kinase, and P38 kinases was inhibited by saracatinib at the submicromolar range.	saracatinib	80-91	mitogen-activated protein kinase 14	Homo sapiens	51-54
20484016-8	2010	Saracatinib also inhibited the expression and secretion of invasion-related molecules interlukin-8, urokinase-type plasminogen activator, and matrix metalloprotease-9.	saracatinib	0-11	plasminogen activator, urokinase	Homo sapiens	100-136
20484016-9	2010	Receptor activator of NF-kappaB ligand (RANKL)-induced osteoclastogenesis and signaling were inhibited by saracatinib in both macrophages and PC-3 cells.	saracatinib	106-117	TNF superfamily member 11	Homo sapiens	40-45
20367532-6	2010	WHAT THE READER WILL GAIN: Readers will gain an insight into the development of therapeutic Src inhibitors, including dasatinib and saracatinib; an understanding of their effects on prostate cancer cells and the bone microenvironment; and emerging clinical data.	saracatinib	132-143	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	92-95
20015594-5	2010	SRC-targeting agents, including dasatinib, saracatinib, and bosutinib, are currently in clinical development for patients with solid tumors.	saracatinib	43-54	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	0-3
19775203-2	2010	We investigated the effect of the orally available Src inhibitor saracatinib (AZD0530) on bone turnover in healthy men.	saracatinib	65-76	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	51-54
19393585-0	2009	Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530.	saracatinib	66-73	SRC proto-oncogene, non-receptor tyrosine kinase	Rattus norvegicus	52-55
20505783-2	2009	Src regulates HNSCC proliferation and tumor invasion, with the Src-targeted small molecule inhibitor saracatinib displaying potent anti-invasive effects in preclinical studies.	saracatinib	101-112	Rous sarcoma oncogene	Mus musculus	63-66
20505783-9	2009	These results suggest that inhibition of Src kinase by saracatinib impairs the pro-invasive activity of HNSCC by inhibiting Src substrate phosphorylation important for invadopodia formation and associated matrix metalloprotease activity.	saracatinib	55-66	Rous sarcoma oncogene	Mus musculus	41-44
20505783-9	2009	These results suggest that inhibition of Src kinase by saracatinib impairs the pro-invasive activity of HNSCC by inhibiting Src substrate phosphorylation important for invadopodia formation and associated matrix metalloprotease activity.	saracatinib	55-66	Rous sarcoma oncogene	Mus musculus	124-127
19509160-0	2009	Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer.	saracatinib	48-55	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	59-62
19509160-1	2009	PURPOSE: To determine the efficacy of AZD0530, an orally active small molecule Src inhibitor, in human pancreatic cancer xenografts and to seek biomarkers predictive of activity.	saracatinib	38-45	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	79-82
19509160-4	2009	Baseline gene expression profiles of differently expressed genes in 16 tumors by Affymetrix U133 Plus 2.0 gene array were used to predict AZD0530 sensitivity in an independent group of eight tumors using the K-Top Scoring Pairs (K-TSP) method.	saracatinib	138-145	thrombospondin 1	Homo sapiens	231-234
19509160-6	2009	Western blot and/or immunohistochemistry results showed that AZD0530 administration resulted in the down-regulation of Src, FAK, p-FAK, p-paxillin, p-STAT-3, and XIAP in sensitive tumor xenografts compared with control tumors.	saracatinib	61-68	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	119-122
19509160-6	2009	Western blot and/or immunohistochemistry results showed that AZD0530 administration resulted in the down-regulation of Src, FAK, p-FAK, p-paxillin, p-STAT-3, and XIAP in sensitive tumor xenografts compared with control tumors.	saracatinib	61-68	protein tyrosine kinase 2	Homo sapiens	124-127
19509160-6	2009	Western blot and/or immunohistochemistry results showed that AZD0530 administration resulted in the down-regulation of Src, FAK, p-FAK, p-paxillin, p-STAT-3, and XIAP in sensitive tumor xenografts compared with control tumors.	saracatinib	61-68	protein tyrosine kinase 2	Homo sapiens	131-134
19509160-6	2009	Western blot and/or immunohistochemistry results showed that AZD0530 administration resulted in the down-regulation of Src, FAK, p-FAK, p-paxillin, p-STAT-3, and XIAP in sensitive tumor xenografts compared with control tumors.	saracatinib	61-68	X-linked inhibitor of apoptosis	Homo sapiens	162-166
19509160-10	2009	One gene pair (LRRC19 and IGFBP2) identified by the K-TSP classifier has high predictive power for AZD0530 sensitivity, suggesting the potential for this gene pair as biomarker for pancreatic tumor sensitivity to AZD0530.	saracatinib	99-106	leucine rich repeat containing 19	Homo sapiens	15-21
19509160-10	2009	One gene pair (LRRC19 and IGFBP2) identified by the K-TSP classifier has high predictive power for AZD0530 sensitivity, suggesting the potential for this gene pair as biomarker for pancreatic tumor sensitivity to AZD0530.	saracatinib	99-106	insulin like growth factor binding protein 2	Homo sapiens	26-32
19509160-10	2009	One gene pair (LRRC19 and IGFBP2) identified by the K-TSP classifier has high predictive power for AZD0530 sensitivity, suggesting the potential for this gene pair as biomarker for pancreatic tumor sensitivity to AZD0530.	saracatinib	99-106	thrombospondin 1	Homo sapiens	54-57
19509160-10	2009	One gene pair (LRRC19 and IGFBP2) identified by the K-TSP classifier has high predictive power for AZD0530 sensitivity, suggesting the potential for this gene pair as biomarker for pancreatic tumor sensitivity to AZD0530.	saracatinib	213-220	leucine rich repeat containing 19	Homo sapiens	15-21
19509160-10	2009	One gene pair (LRRC19 and IGFBP2) identified by the K-TSP classifier has high predictive power for AZD0530 sensitivity, suggesting the potential for this gene pair as biomarker for pancreatic tumor sensitivity to AZD0530.	saracatinib	213-220	insulin like growth factor binding protein 2	Homo sapiens	26-32
19509160-10	2009	One gene pair (LRRC19 and IGFBP2) identified by the K-TSP classifier has high predictive power for AZD0530 sensitivity, suggesting the potential for this gene pair as biomarker for pancreatic tumor sensitivity to AZD0530.	saracatinib	213-220	thrombospondin 1	Homo sapiens	54-57
19293266-0	2009	Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer.	saracatinib	23-30	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	14-17
19293266-0	2009	Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer.	saracatinib	23-30	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	43-46
19293266-0	2009	Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer.	saracatinib	23-30	protein tyrosine kinase 2	Homo sapiens	47-68
19293266-4	2009	DESIGN: PTC and ATC cells were treated with the oral Src inhibitor, AZD0530, to determine the consequences of Src inhibition using growth and invasion assays.	saracatinib	68-75	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	53-56
19293266-7	2009	Instead, we show for the first time that FAK, a critical substrate and effector of Src, is phosphorylated at tyrosine residue 861 (pY861) in PTC and ATC cells, and high levels of phospho-FAK correlate with AZD0530 sensitivity.	saracatinib	206-213	protein tyrosine kinase 2	Homo sapiens	41-44
19293266-7	2009	Instead, we show for the first time that FAK, a critical substrate and effector of Src, is phosphorylated at tyrosine residue 861 (pY861) in PTC and ATC cells, and high levels of phospho-FAK correlate with AZD0530 sensitivity.	saracatinib	206-213	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	83-86
19393585-1	2009	AZD0530, an orally available Src inhibitor, demonstrated potent antimigratory and anti-invasive effects in vitro, and inhibited metastasis in a murine model of bladder cancer.	saracatinib	0-7	Rous sarcoma oncogene	Mus musculus	29-32
19393585-3	2009	AZD0530 inhibited tumor growth in 4/10 xenograft models tested and dynamically inhibited in vivo phosphorylation of Src substrates paxillin and FAK in both growth-inhibition-resistant and -sensitive xenografts.	saracatinib	0-7	SRC proto-oncogene, non-receptor tyrosine kinase	Rattus norvegicus	116-119
19393585-3	2009	AZD0530 inhibited tumor growth in 4/10 xenograft models tested and dynamically inhibited in vivo phosphorylation of Src substrates paxillin and FAK in both growth-inhibition-resistant and -sensitive xenografts.	saracatinib	0-7	protein tyrosine kinase 2	Rattus norvegicus	144-147
19451593-0	2009	Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors.	saracatinib	118-125	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	9-12
19451593-6	2009	RESULTS: AZD0530 and anastrozole together increased p27 and caused greater G(1) cell cycle arrest than either drug alone.	saracatinib	9-16	interferon alpha inducible protein 27	Homo sapiens	52-55
19451593-8	2009	Combined anastrozole/AZD0530 reduced drug resistance and showed greater antitumor efficacy in vivo with greater Src and epidermal growth factor receptor inhibition and a greater increase in p27 and reduction of Ki-67 than either drug alone, supporting further evaluation of these putative predictors of response to combined Src/aromatase inhibition in vivo.	saracatinib	21-28	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	112-115
19451593-8	2009	Combined anastrozole/AZD0530 reduced drug resistance and showed greater antitumor efficacy in vivo with greater Src and epidermal growth factor receptor inhibition and a greater increase in p27 and reduction of Ki-67 than either drug alone, supporting further evaluation of these putative predictors of response to combined Src/aromatase inhibition in vivo.	saracatinib	21-28	epidermal growth factor receptor	Homo sapiens	120-152
19451593-8	2009	Combined anastrozole/AZD0530 reduced drug resistance and showed greater antitumor efficacy in vivo with greater Src and epidermal growth factor receptor inhibition and a greater increase in p27 and reduction of Ki-67 than either drug alone, supporting further evaluation of these putative predictors of response to combined Src/aromatase inhibition in vivo.	saracatinib	21-28	interferon alpha inducible protein 27	Homo sapiens	190-193
19451593-8	2009	Combined anastrozole/AZD0530 reduced drug resistance and showed greater antitumor efficacy in vivo with greater Src and epidermal growth factor receptor inhibition and a greater increase in p27 and reduction of Ki-67 than either drug alone, supporting further evaluation of these putative predictors of response to combined Src/aromatase inhibition in vivo.	saracatinib	21-28	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	324-327
19451593-10	2009	AZD0530-resistant tumors showed activation of bypass pathways including MEK and phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin, raising the possibility that MEK, mammalian target of rapamycin (mTOR), or PI3K inhibitors may augment Src inhibitor efficacy.	saracatinib	0-7	mitogen-activated protein kinase kinase 7	Homo sapiens	72-75
19451593-10	2009	AZD0530-resistant tumors showed activation of bypass pathways including MEK and phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin, raising the possibility that MEK, mammalian target of rapamycin (mTOR), or PI3K inhibitors may augment Src inhibitor efficacy.	saracatinib	0-7	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	80-109
19451593-10	2009	AZD0530-resistant tumors showed activation of bypass pathways including MEK and phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin, raising the possibility that MEK, mammalian target of rapamycin (mTOR), or PI3K inhibitors may augment Src inhibitor efficacy.	saracatinib	0-7	AKT serine/threonine kinase 1	Homo sapiens	117-120
19451593-10	2009	AZD0530-resistant tumors showed activation of bypass pathways including MEK and phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin, raising the possibility that MEK, mammalian target of rapamycin (mTOR), or PI3K inhibitors may augment Src inhibitor efficacy.	saracatinib	0-7	mechanistic target of rapamycin kinase	Homo sapiens	121-150
19451593-10	2009	AZD0530-resistant tumors showed activation of bypass pathways including MEK and phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin, raising the possibility that MEK, mammalian target of rapamycin (mTOR), or PI3K inhibitors may augment Src inhibitor efficacy.	saracatinib	0-7	mitogen-activated protein kinase kinase 7	Homo sapiens	181-184
19451593-10	2009	AZD0530-resistant tumors showed activation of bypass pathways including MEK and phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin, raising the possibility that MEK, mammalian target of rapamycin (mTOR), or PI3K inhibitors may augment Src inhibitor efficacy.	saracatinib	0-7	mechanistic target of rapamycin kinase	Homo sapiens	186-215
19451593-10	2009	AZD0530-resistant tumors showed activation of bypass pathways including MEK and phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin, raising the possibility that MEK, mammalian target of rapamycin (mTOR), or PI3K inhibitors may augment Src inhibitor efficacy.	saracatinib	0-7	mechanistic target of rapamycin kinase	Homo sapiens	217-221
19451593-10	2009	AZD0530-resistant tumors showed activation of bypass pathways including MEK and phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin, raising the possibility that MEK, mammalian target of rapamycin (mTOR), or PI3K inhibitors may augment Src inhibitor efficacy.	saracatinib	0-7	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	255-258
19154462-8	2009	Encouraging results have been obtained in preclinical and clinical studies using Src inhibitors like AZD0530 and dasatinib.	saracatinib	101-108	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	81-84
19372577-0	2009	The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts.	saracatinib	18-25	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	4-7
19372577-3	2009	Therefore, drugs like AZD0530, designed to inhibit Src activity, could selectively interfere with both tumor and osteoclast activity.	saracatinib	22-29	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	51-54
19372577-7	2009	AZD0530 was most effective in inhibiting osteoclast-like cell formation when present at the onset of osteoclastogenesis, suggesting that Src activity is important during the initial phase of osteoclast formation.	saracatinib	0-7	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	137-140
19372577-8	2009	Formation of active phosphorylated c-Src, which was highly present in osteoclast-like cells in cocultures and in peripheral blood mononuclear cell monocultures, was significantly reduced by AZD0530.	saracatinib	190-197	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	35-40
18409068-3	2009	This study aimed to determine the validity of invasion-related biomarkers of activity for AZD0530, a potent Src inhibitor currently in clinical development.	saracatinib	90-97	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	108-111
18409068-9	2009	AZD0530 inhibited tumor growth in a manner independent of dose and inhibited phosphorylation of FAK and paxillin in a dose-dependent manner in a Calu-6 xenograft model.	saracatinib	0-7	protein tyrosine kinase 2	Homo sapiens	96-99
18409068-9	2009	AZD0530 inhibited tumor growth in a manner independent of dose and inhibited phosphorylation of FAK and paxillin in a dose-dependent manner in a Calu-6 xenograft model.	saracatinib	0-7	paxillin	Homo sapiens	104-112
18493848-5	2009	Chronic exposure of both cell types to the Src inhibitor, AZD0530, as a monotherapy resulted in outgrowth of AZD0530-resistant cells, in which Src kinase activity remained suppressed as did their in vitro invasive nature.	saracatinib	58-65	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	43-46
18493848-5	2009	Chronic exposure of both cell types to the Src inhibitor, AZD0530, as a monotherapy resulted in outgrowth of AZD0530-resistant cells, in which Src kinase activity remained suppressed as did their in vitro invasive nature.	saracatinib	58-65	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	143-146
18493848-5	2009	Chronic exposure of both cell types to the Src inhibitor, AZD0530, as a monotherapy resulted in outgrowth of AZD0530-resistant cells, in which Src kinase activity remained suppressed as did their in vitro invasive nature.	saracatinib	109-116	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	43-46
18493848-5	2009	Chronic exposure of both cell types to the Src inhibitor, AZD0530, as a monotherapy resulted in outgrowth of AZD0530-resistant cells, in which Src kinase activity remained suppressed as did their in vitro invasive nature.	saracatinib	109-116	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	143-146
18493848-6	2009	Treatment of both MCF7 and T47D cells with AZD0530 in combination with tamoxifen resulted in a reduction of Src activity together with inhibition of focal adhesion kinase phosphorylation and a complete abrogation of their in vitro invasive behaviour.	saracatinib	43-50	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	108-111
19240653-0	2009	The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells.	saracatinib	18-25	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	4-7
19240653-3	2009	METHODS: This study evaluated the molecular and functional effects of Src inhibitor AZD0530 in human lung cancer cells, by Western blotting and reverse transcription-polymerase chain reaction, and by assays for cell viability, migration, and invasion.	saracatinib	84-91	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	70-73
19240653-5	2009	Clinically relevant, submicromolar concentrations of AZD0530 blocked Src and focal adhesion kinase, resulting in significant inhibition of cell migration and Matrigel invasion.	saracatinib	53-60	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	69-72
19240653-7	2009	AZD0530 gave a potent and sustained blockage of AKT and enhanced the sensitivity to irradiation.	saracatinib	0-7	AKT serine/threonine kinase 1	Homo sapiens	48-51
19098120-6	2009	Phosphorylation of FAK at Tyr(576)/Tyr(577) was inhibited by AZD0530 in a dose-dependent manner both in cell culture and in vitro.	saracatinib	61-68	PTK2 protein tyrosine kinase 2	Mus musculus	19-22
19098120-7	2009	However, there was a substantial difference in the ability of AZD0530 to inhibit Src that was constitutively activated in a cellular context (IC(50) = 2.12 muM) compared with the isolated enzyme (IC(50) = 0.14 muM).	saracatinib	62-69	Rous sarcoma oncogene	Mus musculus	81-84
19216789-4	2009	Here, we investigated the biological effect of the new specific dual Src/Abl kinase inhibitor AZD0530 on Ph+ leukaemic cells.	saracatinib	94-101	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	69-72
19216789-13	2009	CONCLUSION: Our results indicate that AZD0530 targets both Src and Bcr-Abl kinase activity and reduces the leukaemic maintenance by Bcr-Abl.	saracatinib	38-45	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	59-62
19216789-13	2009	CONCLUSION: Our results indicate that AZD0530 targets both Src and Bcr-Abl kinase activity and reduces the leukaemic maintenance by Bcr-Abl.	saracatinib	38-45	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	67-74
19216789-13	2009	CONCLUSION: Our results indicate that AZD0530 targets both Src and Bcr-Abl kinase activity and reduces the leukaemic maintenance by Bcr-Abl.	saracatinib	38-45	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	132-139
19060248-5	2009	AZD0530, a selective Src inhibitor, prevented the TPA-induced proliferation of basal keratinocytes both in vivo and in vitro.	saracatinib	0-7	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	21-24
19117998-7	2009	A Src family kinase (SFK) inhibitor, AZD0530, inhibits androgen-independent growth and migration of the GRP-expressing cell lines, and blocks the nuclear translocation of AR, indicating the involvement of SFK in the aberrant activation of AR and demonstrating the potential use of SFK inhibitor in the treatment of castration-resistant CaP.	saracatinib	37-44	gastrin releasing peptide	Homo sapiens	104-107
19060248-9	2009	Thus, Src inhibitors such as AZD0530 may therefore have chemopreventative properties in patients with hyperproliferative epidermal disorders.	saracatinib	29-36	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	6-9
19235590-1	2009	We hypothesized that co-targeting the epidermal growth factor receptor (EGFR) and Src with the EGFR inhibitor gefitinib and the Src inhibitor AZD0530 would increase growth inhibition and impede migration.	saracatinib	142-149	epidermal growth factor receptor	Homo sapiens	38-70
19235590-1	2009	We hypothesized that co-targeting the epidermal growth factor receptor (EGFR) and Src with the EGFR inhibitor gefitinib and the Src inhibitor AZD0530 would increase growth inhibition and impede migration.	saracatinib	142-149	epidermal growth factor receptor	Homo sapiens	72-76
19235590-1	2009	We hypothesized that co-targeting the epidermal growth factor receptor (EGFR) and Src with the EGFR inhibitor gefitinib and the Src inhibitor AZD0530 would increase growth inhibition and impede migration.	saracatinib	142-149	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	128-131
18924149-7	2009	Src activity in both hypoxic and nonhypoxic BxPC3 tumor regions was suppressed when mice were treated with the Src inhibitor AZD0530 (25 mg/kg/day, 5 days), suggesting that both hypoxic and normoxic tumor regions are accessible to pharmacological Src inhibition.	saracatinib	125-132	Rous sarcoma oncogene	Mus musculus	0-3
18924149-7	2009	Src activity in both hypoxic and nonhypoxic BxPC3 tumor regions was suppressed when mice were treated with the Src inhibitor AZD0530 (25 mg/kg/day, 5 days), suggesting that both hypoxic and normoxic tumor regions are accessible to pharmacological Src inhibition.	saracatinib	125-132	Rous sarcoma oncogene	Mus musculus	111-114
18924149-7	2009	Src activity in both hypoxic and nonhypoxic BxPC3 tumor regions was suppressed when mice were treated with the Src inhibitor AZD0530 (25 mg/kg/day, 5 days), suggesting that both hypoxic and normoxic tumor regions are accessible to pharmacological Src inhibition.	saracatinib	125-132	Rous sarcoma oncogene	Mus musculus	111-114
18613032-10	2009	The selective Src inhibitor, AZD0530, was found to be effective in blocking both cell invasion and anchorage-independent proliferation.	saracatinib	29-36	Rous sarcoma oncogene	Mus musculus	14-17
19117998-7	2009	A Src family kinase (SFK) inhibitor, AZD0530, inhibits androgen-independent growth and migration of the GRP-expressing cell lines, and blocks the nuclear translocation of AR, indicating the involvement of SFK in the aberrant activation of AR and demonstrating the potential use of SFK inhibitor in the treatment of castration-resistant CaP.	saracatinib	37-44	androgen receptor	Homo sapiens	171-173
19117998-7	2009	A Src family kinase (SFK) inhibitor, AZD0530, inhibits androgen-independent growth and migration of the GRP-expressing cell lines, and blocks the nuclear translocation of AR, indicating the involvement of SFK in the aberrant activation of AR and demonstrating the potential use of SFK inhibitor in the treatment of castration-resistant CaP.	saracatinib	37-44	androgen receptor	Homo sapiens	239-241
19117998-8	2009	In vivo studies have shown that AZD0530 profoundly inhibits tumor metastasis in severe combined immunodeficient mice implanted with GRP-autocrine LNCaP cells.	saracatinib	32-39	gastrin releasing peptide	Mus musculus	132-135
18679417-0	2008	Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.	saracatinib	85-92	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	0-3
18679417-3	2008	We sought to investigate the Src-mediated oncogenic pathways and tumor biology using AZD0530, a novel Src family kinase/Abl dual-kinase inhibitor that is entering phase II clinical trials.	saracatinib	85-92	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	29-32
18679417-3	2008	We sought to investigate the Src-mediated oncogenic pathways and tumor biology using AZD0530, a novel Src family kinase/Abl dual-kinase inhibitor that is entering phase II clinical trials.	saracatinib	85-92	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	102-105
18679417-3	2008	We sought to investigate the Src-mediated oncogenic pathways and tumor biology using AZD0530, a novel Src family kinase/Abl dual-kinase inhibitor that is entering phase II clinical trials.	saracatinib	85-92	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	120-123
18679417-5	2008	Furthermore, Src activation is inhibited by AZD0530 in a rapid and dose-dependent manner.	saracatinib	44-51	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	13-16
17394086-5	2007	Inhibition of Src activity using the Src/Abl inhibitor AZD0530 reduced FAK activity, suppressed cell spreading on matrix-coated surfaces and significantly inhibited cell migration.	saracatinib	55-62	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	14-17
17918184-7	2008	Treatment with the dual specific Abl/c-Src kinase inhibitor AZD0530 significantly reduces the growth inhibitory effect of high EGF concentrations, signifying that EGFR induced IRF-1 is responsible for the observed growth inhibition.	saracatinib	60-67	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	33-36
17918184-7	2008	Treatment with the dual specific Abl/c-Src kinase inhibitor AZD0530 significantly reduces the growth inhibitory effect of high EGF concentrations, signifying that EGFR induced IRF-1 is responsible for the observed growth inhibition.	saracatinib	60-67	C-terminal Src kinase	Homo sapiens	37-49
17918184-7	2008	Treatment with the dual specific Abl/c-Src kinase inhibitor AZD0530 significantly reduces the growth inhibitory effect of high EGF concentrations, signifying that EGFR induced IRF-1 is responsible for the observed growth inhibition.	saracatinib	60-67	epidermal growth factor receptor	Homo sapiens	163-167
17918184-7	2008	Treatment with the dual specific Abl/c-Src kinase inhibitor AZD0530 significantly reduces the growth inhibitory effect of high EGF concentrations, signifying that EGFR induced IRF-1 is responsible for the observed growth inhibition.	saracatinib	60-67	interferon regulatory factor 1	Homo sapiens	176-181
18594017-7	2008	RESULTS: Here, we show that inhibition of PLCgamma-1 or c-Src with the PLC inhibitor U73122 or the Src family inhibitor AZD0530 or using dominant-negative constructs attenuated epidermal growth factor (EGF)-stimulated HNSCC invasion.	saracatinib	120-127	phospholipase C gamma 1	Homo sapiens	42-52
18594017-7	2008	RESULTS: Here, we show that inhibition of PLCgamma-1 or c-Src with the PLC inhibitor U73122 or the Src family inhibitor AZD0530 or using dominant-negative constructs attenuated epidermal growth factor (EGF)-stimulated HNSCC invasion.	saracatinib	120-127	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	56-61
18594017-7	2008	RESULTS: Here, we show that inhibition of PLCgamma-1 or c-Src with the PLC inhibitor U73122 or the Src family inhibitor AZD0530 or using dominant-negative constructs attenuated epidermal growth factor (EGF)-stimulated HNSCC invasion.	saracatinib	120-127	heparan sulfate proteoglycan 2	Homo sapiens	42-45
18594017-7	2008	RESULTS: Here, we show that inhibition of PLCgamma-1 or c-Src with the PLC inhibitor U73122 or the Src family inhibitor AZD0530 or using dominant-negative constructs attenuated epidermal growth factor (EGF)-stimulated HNSCC invasion.	saracatinib	120-127	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	58-61
18381431-3	2008	Microarray analyses showed that Id family genes were among the most highly down-regulated by incubation of A549 lung carcinoma cells with the small-molecule Src inhibitor AZD0530.	saracatinib	171-178	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	157-160
18381431-6	2008	PP2, AZD0530, and dominant-negative Src abrogated Id1 promoter activity, which was induced by constitutively active Src.	saracatinib	5-12	inhibitor of DNA binding 1, HLH protein	Homo sapiens	50-53
17704648-2	2007	We here demonstrate that three newly developed dual selective Src/Abl kinase inhibitors (SrcK-I) (AZM559756, AZD0530 and AZD0424) are able to induce apoptosis and cell cycle arrest in BCR-ABL, c-KIT and platelet-derived growth factor-negative lymphoma cell lines.	saracatinib	109-116	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	184-191
17704648-2	2007	We here demonstrate that three newly developed dual selective Src/Abl kinase inhibitors (SrcK-I) (AZM559756, AZD0530 and AZD0424) are able to induce apoptosis and cell cycle arrest in BCR-ABL, c-KIT and platelet-derived growth factor-negative lymphoma cell lines.	saracatinib	109-116	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	193-198
17394086-5	2007	Inhibition of Src activity using the Src/Abl inhibitor AZD0530 reduced FAK activity, suppressed cell spreading on matrix-coated surfaces and significantly inhibited cell migration.	saracatinib	55-62	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	37-40
17394086-5	2007	Inhibition of Src activity using the Src/Abl inhibitor AZD0530 reduced FAK activity, suppressed cell spreading on matrix-coated surfaces and significantly inhibited cell migration.	saracatinib	55-62	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	41-44
17394086-5	2007	Inhibition of Src activity using the Src/Abl inhibitor AZD0530 reduced FAK activity, suppressed cell spreading on matrix-coated surfaces and significantly inhibited cell migration.	saracatinib	55-62	protein tyrosine kinase 2	Homo sapiens	71-74
17064066-4	2006	N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine (AZD0530) inhibits c-Src and Abl enzymes at low nanomolar concentrations and is highly selective over a range of kinases.	saracatinib	122-129	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	140-145
17259559-6	2006	Using the dual specific Src/Abl kinase inhibitor, AZD0530, we have highlighted a central role for Src kinase in promoting the invasive phenotype that accompanies both anti-hormone and anti-growth factor resistance.	saracatinib	50-57	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	98-101
17172405-6	2006	A c-Src inhibitor, AZD0530, was used to analyze the biological effects of pharmacologically inhibiting c-Src kinase activity.	saracatinib	19-26	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	2-7
17172405-6	2006	A c-Src inhibitor, AZD0530, was used to analyze the biological effects of pharmacologically inhibiting c-Src kinase activity.	saracatinib	19-26	C-terminal Src kinase	Homo sapiens	103-115
17173196-10	2006	Compared with that in the control group, the levels of AIF mRNA expression were significantly higher in the groups of H8h and H12h (0.52+/-0.04 and 0.85+/-0.10), indicating that this effect was time-dependent.	saracatinib	118-121	apoptosis inducing factor mitochondria associated 1	Homo sapiens	55-58
17173196-13	2006	Compared with that in the control group, the levels of AIF protein expression were significantly higher in the groups of H8h and H12h (2.07+/-0.15 and 3.12+/-0.19).	saracatinib	121-124	apoptosis inducing factor mitochondria associated 1	Homo sapiens	55-58
17173196-14	2006	The AIF protein expression was increased further in the groups of H8h/R (4.57+/-0.25) and H12h/R (5.71+/-0.27).	saracatinib	66-69	apoptosis inducing factor mitochondria associated 1	Homo sapiens	4-7
17064066-4	2006	N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine (AZD0530) inhibits c-Src and Abl enzymes at low nanomolar concentrations and is highly selective over a range of kinases.	saracatinib	122-129	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	150-153
17064066-6	2006	AZD0530 is a potent inhibitor of tumor growth in a c-Src-transfected 3T3-fibroblast xenograft model in vivo and led to a significant increase in survival in a highly aggressive, orthotopic model of human pancreatic cancer when dosed orally once daily.	saracatinib	0-7	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	51-56
16333527-7	2006	Treatment of TamR cells with the novel Src inhibitor, AZD0530, significantly reduced the amount of activated Src detectable in both cell types whilst having no effect on total Src levels.	saracatinib	54-61	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	39-42
16333527-7	2006	Treatment of TamR cells with the novel Src inhibitor, AZD0530, significantly reduced the amount of activated Src detectable in both cell types whilst having no effect on total Src levels.	saracatinib	54-61	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	109-112
16333527-7	2006	Treatment of TamR cells with the novel Src inhibitor, AZD0530, significantly reduced the amount of activated Src detectable in both cell types whilst having no effect on total Src levels.	saracatinib	54-61	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	109-112
16333527-8	2006	AZD0530 significantly suppressed the motile and invasive nature of TamR cells in vitro, reduced basal levels of activated focal adhesion kinase (FAK) and paxillin and promoted elongation of focal adhesions.	saracatinib	0-7	protein tyrosine kinase 2	Homo sapiens	122-143
16333527-8	2006	AZD0530 significantly suppressed the motile and invasive nature of TamR cells in vitro, reduced basal levels of activated focal adhesion kinase (FAK) and paxillin and promoted elongation of focal adhesions.	saracatinib	0-7	protein tyrosine kinase 2	Homo sapiens	145-148
16113095-5	2005	Candidate drugs for several of these targets are currently being evaluated; for example, the prenylation inhibitor AZD3409, a mimetic of the CAAX box of K-Ras, inhibits protein farnesyl and geranylgeranyl tranferases and a novel, selective, orally active Src kinase inhibitor AZD0530 have entered Phase I clinical trials and may have utility in breast cancer therapy.	saracatinib	276-283	KRAS proto-oncogene, GTPase	Homo sapiens	153-158